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ABBREVIATIONS
AMPK Adenosine monophosphate-activated protein kinase
Bcl-2 B-cell lymphoma 2
Bcl-xL B-cell lymphoma-extra large
BSA Bovine serum albumin
cCasp3 Cleaved caspase-3
CI Confidence interval
CSV Comma-separated values
DMSO Dimethyl sulfoxide
DSB Double-stranded break
EOC Epithelial ovarian cancer
FBS Fetal bovine serum
HGSOC High-grade serous ovarian cancer
HR Homologous recombination
HRD Homologous recombination deficiency
IR Ionizing radiation
LKB1 Liver kinase B1
Macro Macroinstruction
NF-B Nuclear factor kappa-light-chain-enhancer of activated B cells
PARP Poly (ADP-ribose) polymerase
PBS Phosphate-buffered saline
PBS++ Phosphate-buffered saline containing calcium and magnesium
PFA Paraformaldehyde
P/S Penicillin-streptomycin
SET Solid, pseudo-endometrioid and/or transitional cell carcinoma-like
SSB Single-stranded break
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1. INTRODUCTION
1. 1. Ovarian cancer
1. 1. 1. Ovarian cancer prevalence, prognosis, and mortality
Ovarian cancer is typically a late-life disease, usually occurring after menopause, the median age at
diagnosis being 63 (Ozols et al., 2004). Despite constituting just three percent of cancers in women
(Bodmer et al., 2011), it is the most fatal cancer of the female reproductive system as well as the eighth
cause of cancer-related deaths in females worldwide (Ozols et al., 2004; Ferlay et al., 2015). Early
detection is often impeded by a sustained clinically silent onset, the lack of specific symptoms as well as
proper screening programs, and even though the initial treatments involving cytoreductive surgery and
chemotherapy are often successful, the disease recurs, metastasizes, and becomes drug-resistant for most
patients, ultimately resulting in their death (Chien et al., 2007). According to the latest publication of
cancer statistics, the overall five-year survival rate of patients with ovarian cancer is 48 % (Siegel et al.,
2020).
1. 1. 2. Ovarian cancer classification
Epithelial ovarian cancer (EOC) constitutes the majority of ovarian cancers, around ninety percent
(Aletti et al., 2007). The other types are ovarian stromal tumors and ovarian germ cell tumors (Aletti et
al., 2007).
According to the newest dualistic model of ovarian carcinogenesis, EOC can be categorized into Type
1 and Type 2 (Kurman et al., 2016). Tumors belonging to the Type 1 category that often has a better
prognosis originate from benign lesions embedded on the ovary followed by a slow malignant
metamorphosis (Kurman et al., 2016). In contrast, more aggressive Type II tumors usually arise from
intraepithelial carcinomas in the fallopian tube, followed by rapid dissemination to the inside and the
outside of the ovary, resulting in a worse prognosis (Kurman et al., 2016).
In addition, EOC can be divided into the following histologically different classes based on tissue
architecture resemblance: serous, mucinous, endometrioid, clear cell, transitional (Brenner), squamous,
mixed, and undifferentiated, each with specific morphologic and genetic variations (Bell, 2005; Desai et
al., 2014). Approximately three-quarters of EOCs belong to the serous category, which based on the level
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of cellular aberration can be further classified into low-grade and high-grade subtypes, the latter being
more common (Berns et al., 2012; Desai et al., 2014).
High-grade serous ovarian cancer (HGSOC) falls into the Type II category of EOCs (Kurman et al.,
2016). Being the most prevalent and aggressive subtype, it constitutes 70-80 % of deaths from ovarian
cancer (Bowtell et al., 2015).
1. 1. 3. Risk and protection factors of HGSOC
Familial history of HGSOC is one of the risk factors for developing the disease (Webb et al., 2017).
The most common hereditary predisposition is germline mutations in BRCA1 or BRCA2 genes,
contributing up to 50 % lifetime risk of the disease, compared to 1,4 % risk in the general population
(Boyd, 2003; Webb et al., 2017). Since BRCA1 and BRCA2 mutations are also associated with breast
cancer, familial and personal history of breast cancer also increases HGSOC risk (Webb et al., 2017;
Stewart et al., 2018). In addition, HGSOC risk can be elevated by various low-penetrance mutations in
other genes, for example, BRIP1, RAD1C, RAD1D, PALB2, and BARD1 (Lisio et al., 2019). The
connection between these genes is that they participate in homologous recombination (HR)-mediated
DNA repair, which is an important pathway in HGSOC pathophysiology (Lisio et al., 2019).
Furthermore, three additional loci have been associated with HGSOC susceptibility: at 2q13, 8q24.1, and
12q24.31 (Phelan et al., 2017). Finally, numerous factors have been associated with the decreased risk
of HGSOC, including a smaller number of ovulatory events, (multi)parity, breastfeeding, tubal ligation,
and the use of oral contraceptives (estrogen and progestin), whereas the use of hormone (estrogen)
replacement therapy during menopause as well as having certain other medical conditions like Lynch
syndrome, pelvic inflammatory disease, and endometriosis increase the risk of the disease (Stewart et al.,
2018; Lisio et al., 2019).
1. 1. 4. HGSOC properties
Cytological features of HGSOC include extreme nuclear atypia, big, pleomorphic, and
hyperchromatic nuclei, multinucleation, pronounced nucleoli, and high mitotic index (Lisio et al., 2019).
Morphologically HGSOCs can be divided into two groups: the usual type and a SET variant (also known
as “solid, pseudo-endometrioid and/or transitional cell carcinoma-like”), whereas molecularly they can
be divided into immunoreactive, differentiated, proliferative, and mesenchymal types, based on gene
expression signatures (Kurman et al., 2016). The morphologically usual type of HGSOC often presents
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as a solid cell mass with slit-like gaps and necrotic areas, and is arranged in a papillary, glandular, or
cribriform fashion, while the SET variant presents as a solid cell mass resembling endometrioid or
transitional cell carcinomas, and is characterized by a higher mitotic index and larger numbers of tumor-
infiltrating lymphocytes (Kurman et al., 2016). The molecular types of HGSOC have not been revealed
to correlate in any way with the morphological types, but associations between molecular types and
clinical outcomes have been made, the immunoreactive type providing survival advantage, while
proliferative and mesenchymal types having worse prognosis (Konecny et al., 2014; Kurman et al.,
2016).
Moving on to the genetic features of HGSOC, methylation in the promoters of 168 genes has been
observed, as well as 113 focal DNA copy number alterations due to profound genomic instability of
HGSOC (Cancer Genome Atlas Research Network, 2011). The most prevalent are CCNE1, MYC, and
MECOM gene amplifications (Cancer Genome Atlas Research Network, 2011). However, the single
most prominent feature of HGSOC is TP53 mutation (Kurman et al., 2016). Somatic mutations in other
genes are infrequent, but may occasionally occur in NF1, CDK12, and RB1 genes (Cancer Genome Atlas
Research Network, 2011). Also, BECN1 and LC3 genes associated with autophagy can be mono-
allelically deleted in HGSOC (Delaney et al., 2017). Of particular interest are germline and sometimes
somatic mutations of BRCA1 and/or BRCA2 genes, occurring in up to 23 % of HGSOCs (Hennessy et
al., 2010; Cancer Genome Atlas Research Network, 2011). In addition, BRCA1 promoter methylation is
common, making up 10-20 % of HGSOCs (Konstantinopoulos et al., 2015). As a result, BRCA1/2, which
is a tumor suppressor gene, is often either genetically or epigenetically inactivated in HGSOC.
Alterations in BRCA1 and BRCA2 genes have been associated with the defective HR pathway of DNA
repair, which is present in approximately half of HGSOCs (Cancer Genome Atlas Research Network,
2011). An important observation is that BRCA-mutant patients have better five-year survival compared
to the non-mutant ones (Bolton et al., 2012), demonstrating that defective HR is an important element to
consider when studying HGSOC. Other pathways that can also be altered in HGSOC include RB1,
PI3K/RAS, PIK3/AKT pathways, as well as FOXM1 transcription factor pathway (it is often activated),
and less frequently – NOTCH signaling pathway (Cancer Genome Atlas Research Network, 2011).
1. 1. 5. Homologous recombination
Many chemotherapeutic agents used in cancer treatment such as platinum and platinum analogs bind
to purine DNA bases and cause intra- and inter-strand crosslinks that can then create double-stranded
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breaks (DSBs) in the DNA (Kelland, 2007; Zhang et al., 2007). DSBs can also be produced by ionizing
radiation (IR) and other external DNA damaging agents or they can be formed from accumulated
unrepaired single-stranded breaks (SSBs) (Haince et al., 2005). DSBs are detrimental to cells and lead to
cell cycle arrest, which in turn result in programmed cell death (Kelland, 2007). The mechanism of action
in DNA-damaging cancer treatment is precisely based on this idea that the accumulation of DNA damage
will destroy cancer cells (Haince et al., 2005). However, DSBs also activate DNA damage recognition
and repair pathways, limiting the treatment effectiveness (Kelland, 2007). In HGSOC, the prominent
DNA repair pathway that influences chemotherapy outcome is HR (Konstantinopoulos et al., 2015).
During HR which occurs in late S and G2 phases of the cell cycle, DSBs are repaired by aligning the
break with homologous DNA sequence, present on the newly replicated sister chromatid (Kennedy et
al., 2006; Damia et al., 2007). First, the 3′ ends on both flanks of a DSB are resected, then the sequence
from the undamaged sister chromatid is accessed by the complementary 3′ advancing strand from the
damaged homologous chromosome and is used as a template by a DNA polymerase (Khanna et al.,
2001). When the strand extension is long enough to cover the area of the DSB, the 3′ end of the advancing
strand reverts to the initial chromosome followed by a continuation of replication (Khanna et al., 2001).
HR is a very accurate way of repairing DSBs (Hoeijmakers, 2007). In case it is not available, cells can
use another DSB repair pathway, non-homologous end joining, which is error-prone, because the break
ends are simply processed and directly ligated without using a complementary template (Kennedy et al.,
2006; Hoeijmakers, 2007).
Paradoxically, cancer cells initially benefit from genomic instability, because it fuels tumor
progression, but disrupted DNA repair pathways, the main cause for genomic instability, results in
heightened sensitivity to DNA-damaging chemotherapeutic agents (Kennedy et al., 2006). Defects in
HR-mediated DNA repair causing homologous recombination deficiency (HRD) are a major reason for
the initially successful response to chemotherapy in HGSOC treatment (Konstantinopoulos et al., 2015;
Testa et al., 2018). The aforementioned case of germline BRCA-mutated patients is the most distinct
example. Patients with BRCA-mutated, that is, HR-deficient tumors also benefit from the use of poly
(ADP-ribose) polymerase (PARP) inhibitors (Fong et al., 2009; Moore et al., 2018). The PARP
superfamily of proteins participate in repairing SSBs, so when PARP proteins are inhibited, unrepaired
SSBs accumulate and cause DSBs, which cannot be repaired due to HR deficiency (Fong et al., 2009).
When used in combination with DNA-damaging agents, PARP inhibitors make the treatment more
efficient and selective, sparing normal healthy cells where HR is intact (Haince et al., 2005; Fong et al.,
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2009). However, genetic and epigenetic alterations in HR-related genes are present in roughly half of
HGSOCs (Konstantinopoulos et al., 2015). This group of patients benefits from existing drug treatments,
while clinical outcomes for the remainder of patients remain poor, as there are no alternative treatment
options at the moment.
1. 2. Metformin
1. 2. 1. Repurposing metformin
Considering the poor prognosis and high mortality of HGSOC, there is a need to determine novel
targeted therapeutic approaches to improve treatment and patients’ survival. One therapeutic strategy
involves the development of an entirely new drug, but this approach has a high probability of failure, and
it may take 10-17 years and cost over USD 800 million to achieve this goal (Tobinick, 2009). An
alternative approach is drug repositioning, in which drugs that are already available for the treatment of
some other disease(s) are put into use for the improved treatment of cancer (Tobinick, 2009).
Metformin hydrochloride, or simply metformin, derived from the Galega officinalis plant, is a
biguanide class of hypoglycemic drug that is widely prescribed to people with type-2 diabetes (Kumar
et al., 2013; Sanchez-Rangel et al., 2017). Interestingly, an association has been made between metformin
intake as part of anti-diabetic medication and improved survival in ovarian cancer (Kumar et al., 2013).
In fact, after the initial epidemiologic findings that metformin taken by diabetic patients is associated
with a lower cancer risk as well as lower cancer-related mortality (Evans et al., 2005; Bowker et al.,
2006), many studies have been conducted with various types of tumors. These studies have shown that
metformin can inhibit the growth of cancer cells in vitro, namely, lung (Ashinuma et al., 2012), pancreatic
(Kisfalvi et al., 2009), colon (Zakikhani et al., 2008), rectal (Park et al., 2019), renal (Liu et al., 2013),
prostate (Ben Sahra et al., 2008), breast (Zakikhani et al., 2006), as well as ovarian (Gotlieb et al., 2008).
For many of these cancer types, the initial findings from cell culture experiments are since supported by
evidence from in vivo studies as well, usually using mouse models.
For ovarian cancer specifically, it has been demonstrated that metformin suppresses cancer growth
and enhances sensitivity to chemotherapeutic agents both in vitro and in vivo in mice (Lengyel et al.,
2015). In addition, ovarian cancer cells have been shown to even overcome resistance to
chemotherapeutic agents as evidenced by the induced apoptosis and augmented autophagy after
metformin treatment in vitro (Yang et al., 2019). Furthermore, it has been discovered that metformin is
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able to limit the development and expansion of ovarian cancer stem cells in vitro and in mice in vivo
(Shank et al., 2012).
1. 2. 2. Anti-neoplastic mechanisms of metformin in ovarian cancer
Metformin is thought to suppress carcinogenesis indirectly by obstructing the insulin / insulin-like
growth factor 1 pathway leading to reduced insulin levels (Hijaz et al., 2016). Possible direct mechanisms
of anti-cancer effects of metformin are currently being investigated, but they remain poorly understood.
Among the studied molecular pathways in ovarian cancer, metformin has first been shown to restrict
cell growth by increasing 5′ adenosine monophosphate-activated protein kinase (AMPK) activity
(Gotlieb et al., 2008). In addition, liver kinase B1 (LKB1) has been found to be necessary for activating
AMPK (Rattan et al., 2011a/b). Upon the activation of the LKB1-AMPK pathway, the signaling through
the mammalian target of rapamycin pathway is suppressed, resulting in reduced cell proliferation (Rattan
et al., 2011a/b).
It has also been revealed that metformin can induce apoptosis in ovarian cancer cells by reducing
mitochondria-associated B-cell lymphoma 2 (also known as Bcl-2) and B-cell lymphoma-extra large
(also known as Bcl-xL) protein expression and increasing Bax and Cytochrome c expression (Patel et
al., 2015). Furthermore, metformin has been found to generate anti-cancer effects in chemoresistant
ovarian cancer cells by diminishing protein kinase B, or Akt, expression via the regulation of
mitochondrial E3 ubiquitin protein ligase 1 expression (Lee et al., 2019).
Moreover, metformin inhibits cell proliferation of chemoresistant ovarian cancer cells by decreasing
the mRNA expression of inflammatory cytokines and nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-B) signaling pathway, which are typically activated by chemotherapy and
associated with chemoresistance (Dos Santos Guimarães et al., 2018). Repressed interleukin 6 secretion
via the inhibition of NF-B signaling by metformin was also found to inactivate ovarian cancer stromal
fibroblasts, resulting in constrained tumor development in mice (Xu et al., 2018). Additionally, in vitro
experiments revealed that metformin represses platelet-mediated ovarian cancer angiogenesis and growth
(Erices et al., 2017) as well as adipocyte-mediated adipogenesis and tumor expansion and progression
(Tebbe et al., 2014).
1. 2. 3. Metformin and DNA damage
Currently, there is controversy over the metformin effect on DNA damage.
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One proposed concept is that the reason behind the general anti-tumorigenic effect of metformin is its
ability to prevent DNA damage and boost DNA damage repair, including the HR pathway, this way
protecting against genomic instability which is a common characteristic of cancer cells (Najafi et al.,
2018). For instance, one study has shown that metformin diminishes DNA damage due to the suppression
of mitochondrial complex I followed by the disruption of mitochondrial respiration and cellular
metabolism, which decreases reactive oxygen species and oxidative stress (Algire et al., 2012). Another
study has presented decreased DNA damage owing to metformin treatment in human lung carcinoma,
epidermoid carcinoma, and normal lymphoblastoid cells (Halicka et al., 2011). There is also a study that
has demonstrated that metformin protects against ultraviolet C-induced DNA damage and increases DNA
repair in lung cancer cells (Lee et al., 2016).
On the other hand, there are studies indicating a different side of metformin effects. Metformin has
been found to increase oxidative DNA damage under oxidative conditions (Ohnishi et al., 2016), to
enhance DNA damage in Chinese hamster ovary cell line CHO-K1 (Amador et al., 2012), and to intensify
IR-induced DNA damage in pancreatic cancer cells via AMPK thus improving the efficiency of radiation
treatment (Fasih et al., 2014). Also, it has been shown that metformin reduces DNA repair in human
hepatoma cells exposed to IR via abatement of adenosine triphosphate production (Liu et al., 2012) as
well as in human lung cancer cells by suppressing the expression of a p38 mitogen-activated protein
kinase-dependent set of DNA repair proteins, excision repair cross-complementing 1 (Tseng et al., 2013).
A study of colorectal cancer cells has even revealed that metformin impedes repair of IR-induced DNA
damage by decreasing the expression of several HR-related DNA repair proteins in vitro and in vivo,
improving radiosensitivity even in radioresistant cells and tumors (Jeong et al., 2015).
Nevertheless, there are also studies that have not found any effect of metformin on DNA damage. For
example, metformin was not able to protect against the induced oxidative DNA damage in cultured
human peripheral blood lymphocytes (Onaran et al., 2006) or induce DNA damage in SKOV3 and A2780
ovarian cancer cell lines (Hijaz et al., 2016). However, it is worth noting that the latter are not HGSOC
cell lines.
It could be that the metformin effect depends on cell type. For ovarian cancer cells specifically, the
data on this matter is very scarce. Ovarian cancers (and thus ovarian cancer cell lines) display high intra-
and especially inter-patient genomic heterogeneity. Different in vitro studies have often used different
cell lines, and conceivably the metformin effect on DNA damage could differ between cell lines. Because
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of the varying results from metformin and DNA damage studies and the limited data from them on
ovarian cancer, there is a need to examine this area further.
In ovarian cancer, the aspect of DNA damage in relation to HR is of particular importance. Even those
patient tumors that initially have been declared as HR-deficient still have a sub-population of cells that
are HR-proficient. These HR-proficient cells survive chemotherapy, eventually continue their expansion,
the patient relapses, and after a certain number of chemotherapy treatments, the patient becomes
chemoresistant. This is called acquired resistance to chemotherapy (Chien et al., 2007;
Konstantinopoulos et al., 2015). The situation is even worse for those patients whose cancer is identified
as HR-proficient from the very beginning. They can be considered to have intrinsic resistance to
chemotherapy. The existing chemotherapeutic treatment has no beneficial effect at all on roughly 20 %
of HGSOCs (Chien et al., 2007).
Since metformin has been associated with improved survival rate in diabetic ovarian cancer patients,
and HR status is of significant importance for chemotherapeutic outcome in this disease, one can
hypothesize that metformin may have the ability to induce an HR-deficient state in cancer cells,
sensitizing them to treatment. While this study did not examine HR directly, it investigated HR indirectly
by observing the effect of metformin on: (i) DNA damage, (ii) cell proliferation, and (iii) apoptosis.
These read-outs were obtained for two commercially available HGSOC cell lines with known HR status:
OVCAR4 (HR-proficient) and Kuramochi (HR-deficient) (Domcke et al., 2013; Tumiati et al., 2018;
Tumiati, in preparation).
2. AIMS
A) To inspect the effects of metformin on DNA damage, proliferation, and apoptosis in two HGSOC cell
lines in vitro using metformin at varying concentrations and treatment times.
B) To test whether metformin pre-treatment (with selected concentrations and treatment times) changes
the capacity of HGSOC cells in vitro to respond to irradiation-induced DNA damage.
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3. MATERIALS AND METHODS
Three experiments were performed in total. The workflow consisted of: 1) cell culture, 2) irradiation
(only in the third experiment), 3) cell fixing and staining by indirect immunofluorescence, 4) high-
content analysis, and 5) computational data processing and analysis. Reagents, equipment, and other
resources are listed in Appendix A.
3.1. Cell Culture
Cell culture was performed in a laminar flow cabinet in a near-sterile environment. Two commercial
HGSOC cell lines were used: Kuramochi as HR-deficient, and OVCAR4 as HR-proficient cell line. Both
types of cells were initially frozen in cryogenic vials. One vial per cell line was thawn to initiate cell
culture. Cells were cultured in RPMI 1640 growth medium supplemented with 10 % fetal bovine serum
(FBS), 2 mM glutamine, and 1 % penicillin-streptomycin (P/S), and split and frozen as needed
throughout the experimental part of the study.
3.1.1. Culturing the cells from cryogenic vials
Each of the two cryogenic vials (one for each cell line) contained 1 ml of cells and growth medium
mixture with 10 % dimethyl sulfoxide (DMSO). The vials were first incubated in a 37 ⁰C water bath for
about 1 minute until their contents thawed. Their whole contents were transferred to 50-ml centrifuge
tubes that each contained 10 ml of warm (37 ⁰C) growth medium. The tubes were centrifuged at 1250
rpm and 22 ⁰C for 5 minutes, and after discarding the supernatant, 10 ml of fresh warm medium was
poured onto the cell pellets. The cells were resuspended in the medium and transferred to two 100-mm
culture dishes per cell line. The dishes were placed in an incubator (37 ⁰C, 5 % CO2) and cells were left
to grow for ~72 hours.
3.1.2. Passaging and freezing the cells
When the cells reached ~80-90 % confluence, they were either passaged into more dishes or frozen.
For both purposes, first, the old medium from each dish was discarded, then, the cells were washed with
5 ml of phosphate-buffered saline (PBS). The PBS was discarded, 1 ml of 0,25 % trypsin/EDTA was
added to each dish, and dishes were placed in an incubator at 37 ⁰C for 7-8 minutes. After that, the dishes
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were slapped on the side a few times and checked under a microscope to see whether the cells had
detached from the bottom. If necessary, dishes were returned to the incubator for a few more minutes.
When most of the cells had detached, 5 ml of warm medium was poured onto each dish, and after
pipetting a few times, the content of each dish was transferred to 50-ml centrifuge tubes. All tubes were
centrifuged at 1250 rpm and 22 ⁰C for 5 minutes, discarding the supernatant afterward.
For the passaging procedure, 20-30 ml of warm medium was poured to each tube. Then, the cell pellets
were mixed with the media, and the content of each tube was transferred to two-three 100-mm culture
dishes. Finally, the dishes were placed in an incubator, leaving the cells to grow there for ~72 hours.
For the freezing procedure, 2 ml of medium with 10 % DMSO was transferred to each tube with a cell
pellet, and the pellet was resuspended. Finally, this mixture was transferred to cryogenic vials (1 ml per
vial), the vials were snap-frozen in a freezing container at -80 ⁰C, and transferred to -150 ⁰C for long-
term storage.
3.1.3. Seeding the cells
One dish per cell line was used for seeding into 96-well plates after the cells reached ~80-90 %
confluence. In the first experiment, cells were thawed from cryogenic vials approximately 72 hours
earlier. In the second and third experiments, cells were kept in long-term culture and regularly passaged.
The procedure began with removing the old medium from the dishes, rinsing with 5 ml of PBS,
dissociating the cells with 1 ml of 0,25 % trypsin/EDTA, and incubating for 7-8 minutes. When the cells
were freely floating in the dishes, they were mixed with 9 ml of warm media and then moved to 50-ml
centrifuge tubes.
After that, cells were counted as follows. 10 µl of the cell suspension from each tube was mixed with
10 µl of trypan blue. 10 µl of this mixture was transferred into a chamber in a cell counting slide to be
counted in a cell counter. In the first experiment, there were 4,68 x 105 Kuramochi cells and 9,41 x 105
OVCAR4 cells, in the second experiment, 3,65 x 105 and 6,61 x 105, and in the third experiment, 3,98 x
105 and 4,72 x 105 cells per 1 ml respectively. The volume of medium after centrifugation was adjusted
such that 3000 cells were seeded per well in the first experiment, and 5000 cells in the second and the
third experiments, in a total volume of 100 µl per well.
Cells were dispensed into 96-well plates (according to the pattern shown in figure 1), and then plates
were placed in an incubator for 24 hours to allow the cells to adhere to the bottom of the wells (figure 2).
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Figure 1. Schematic views of the
96-well plates throughout the
experimental part.
Each well had a replicate well.
Black wells mark the occupied
wells in the plates. Lines
“Kuramochi” and “OVCAR4” on
the left next to the rows marked by
letters indicate which cell line was
seeded in that row. Above the
numerical values of the columns,
the numbers indicate the metformin
(met.) concentrations (mM) used in
the columns below them (one
concentration for two columns due
to the duplicate wells); columns 1-2
did not include any metformin, the
media from the seeding part was left
untouched there, i.e., these are
control wells. The linear text fields
on the right indicate the primary
antibody combinations used in the
rows next to them.
A – The pattern used for all of the
plates in the first experiment; B –
The pattern used for all of the plates
in the second experiment; C – The
pattern used for all of the plates in
the third experiment.
3.1.4 Testing different metformin concentrations
In all three experiments, the cells were exposed to varying concentrations of metformin (figures 1-2).
Metformin solution of the highest concentration was always made first by dissolving the weighted
metformin powder amount in the appropriate volume of warm growth medium, and then filtering the
solution. From this solution, serial dilutions were prepared to obtain the desired lower concentrations.
The first experiment tested the effect of metformin solutions of 0,5 mM, 5 mM, and 25 mM
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concentrations. The second experiment included 5 mM, 10 mM, 15 mM, and 20 mM metformin
concentrations. In the third and last experiment, 0,5 mM, 5 mM, 10 mM, and 20 mM metformin
concentrations were used.
After removing the old media from the wells (with the exception of the no-metformin control wells in
columns 1 and 2), 100 µl of the prepared metformin solutions were put to the appropriate wells (according
to the patterns shown in figure 1). After adding the metformin solutions, the plates were placed in an
incubator.
Figure 2. Schematic visualization of the set-up of each experiment.
3.1.5. Testing different metformin treatment lengths
In addition to testing the effect of different metformin concentrations, I also tested different treatment
lengths (figure 2). In the first experiment, one plate was kept in the incubator for 24 hours, another plate
for 48 hours, and the last one remained for 72 hours. These plates are referred to as the “24h plate”, the
“48h plate”, and the “72h plate”. The second experiment included only 24h and 48h treatments; the plates
are called the “24h plate” and the “48h plate” respectively. The third experiment had more variations due
to the irradiation part, described next (section 3.2). In the third experiment, the duration of in-plate
metformin treatment prior to irradiation was either 24 hours or 48 hours, and the subsequent incubation
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was either for 4 hours or 24 hours. The non-irradiated counterpart plates were consequently incubated
while affected with metformin either for 28 hours, 48 hours, 52 hours, or 72 hours. The next paragraph
gives a more detailed explanation of this rationale, at the same time indicating the names of the plates
used in this experiment.
3.2. Irradiation
The third experiment additionally included DNA damage induction via irradiation after metformin
treatment (figure 2). The cells in half of the plates (4 out of 8) were exposed to 5 Gy of IR. Two plates
were irradiated after 24 hours of metformin treatment. Afterward, both were returned to the incubator
and one remained there for 4 hours (from now one referred to as the “24h+IR+4h plate”), and the other
one for 24 hours (named as the “24h+IR+24h plate”). That is, the cellular properties were checked at two
time points: 4 hours and 24 hours after irradiation. The other two plates were irradiated after 48 hours of
metformin treatment. Likewise, one of these two plates stayed in the incubator afterward for 4 hours
(called the “48h+IR+4h plate”), and the other one for 24 hours (referred to as the “48h+IR+24h plate”).
The other half of the plates (the remaining 4) were not irradiated and served as a non-irradiated control.
Their time spent in the incubator matched each one of the irradiated plates. This thus created the
variability in the incubation hours described in the earlier section. The non-irradiated plates were marked
as the “24h+no IR+4h plate”, the “24h+no IR+24h plate”, the “48h+no IR+4h plate” and the “48h+no
IR+24h plate”.
3.3. Cell fixing and staining
These procedures were performed in a normal laboratory environment (i.e., no extra sterility measures
were taken).
3.3.1. Rinsing and fixing the cells
The procedure was performed for every plate in all three experiments after the desired metformin
treatment durations, and in the case of the third experiment, at the above-specified time points after
irradiation.
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First, the media was discarded from the wells, and the cells were washed with 100 µl of PBS. Then,
the cells were fixed using 100 µl of 2 % paraformaldehyde (PFA) diluted in phosphate-buffered saline
containing calcium and magnesium (PBS++) at 4 ⁰C for 10 minutes. After discarding the fixative, the
cells were rinsed with 100 µl of PBS. Afterward, the wells were replenished with 100 µl of PBS, the
plates were sealed with laboratory film and stored in 4 ⁰C until the staining procedure.
3.3.2. Staining the cells
PBS was removed from the wells, and the cells were permeabilized with permeabilization buffer
(consisting of PBS++ with 0,2 % Triton X-100) for 20 minutes. After discarding the permeabilization
buffer, the cells were washed three times with 100 µl of staining buffer (consisting of PBS with 0,5 %
bovine serum albumin (BSA), 0,15 % glycine, and 0,1 % Triton X-100) on a see-saw rocker for 5 minutes
each time, followed by blocking with 100 µl of staining buffer for 30 minutes, again on a rocker.
In the meantime, primary antibodies were diluted in staining buffer. Details on primary antibodies,
the function of the proteins they detect, and dilution ratios can be found in table 1. Due to the identical
host species in which some primary antibodies were raised, it was necessary to perform two double
stainings in order to differentiate the signals. One row of each cell line received the combination of
γH2AX and Ki67, while the other row, γH2AX and cleaved caspase-3 (cCasp3) antibodies appropriately
diluted in staining buffer (figure 1). Each well was filled with 50 µl of the appropriate compound, then
the plates were sealed with laboratory film and left for overnight incubation at 4 ⁰C in order for the
primary antibodies to recognize and bind to their epitopes in the cells.
The next day, primary antibodies were discarded from the wells, and the cells were washed three times
with 100 µl of staining buffer on a rocker at room temperature for 5 minutes each time. Meanwhile, two
secondary Alexa-conjugated antibodies were diluted in staining buffer (table 1). These secondary
antibodies bind to the primary antibodies and have a fluorescent tail which is detectable by
epifluorescence microscopy. Every occupied well was filled with 50 µl of the secondary antibodies and
staining buffer mixture, and then the plates were left for 1 hour at room temperature in the dark, as
secondary antibodies need to be protected from light. After incubation, secondary antibodies were
discarded from the wells, and the cells were washed three times with 100 µl of staining buffer on a rocker
for 5 minutes each time while protecting from light. Then, the cells were counterstained with 100 µl of
2 µg/ml Hoechst dye diluted in PBS. Hoechst was used to visualize nuclei. After approximately 7-8
minutes in the dark, the Hoechst stain was discarded, the cells were rinsed with 100 µl of PBS, and the
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wells were replenished with 100 µl of PBS for imaging. Finally, the plates were sealed with laboratory
film, wrapped in foil to protect from light, and stored in 4 ⁰C until imaging.
Table 1. Primary and secondary antibodies used in the experiments.
Antibody Dilution Ratio
The Process that the Antibody
Allows to Visualize
Primary Antibodies
Mouse anti-γH2AX
(abcam, 22551)
1:1000 DNA damage
Rabbit anti-Ki67
(abcam, 15580)
1:1000 Proliferation
Rabbit anti-cCasp3
(Cell Signaling Technology, 9664)
1:300 Apoptosis
Secondary Antibodies
Goat anti-Mouse Alexa 488
(Molecular Probes, A 11029)
1:1000 DNA damage
Goat anti-Rabbit Alexa 647
(Molecular Probes, A 21245)
1:1000 Either proliferation or apoptosis
3.4. Automated fluorescence image acquisition with a high-content screening system
The plates from the first experiment were imaged with a high-content screening system Thermo
Cellinsight. Separate protocols were created for each of the three plates. The main parameter that required
adjusting between the protocols was exposure time. Firstly, different exposure times were needed for
different channels: channel 1, which visualizes nuclei (Hoechst dye); channel 2, which displays DNA
damage (γH2AX); and channel 3, which shows either proliferation (Ki67) or apoptosis (cCasp3). Once
the appropriate values for exposure time were determined for the 24h plate, 5 fields of every well were
arbitrarily chosen to be scanned. After scanning the first plate, the starting protocol was applied to the
second plate (i.e., 48h plate), and exposure times were slightly adjusted according to the preview on the
screen, following the scanning of 5 random fields. Finally, the same procedure was carried out for the
third, 72h plate.
Due to changes in instrumentation in the Biomedicum bioimaging facility during the course of this
thesis project, the plates from the second and third experiments were imaged with a different high-content
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screening system, ImageXpress Pico. Two protocols were created for the two double stainings. Similarly
to Thermo Cellinsight, exposure times were separately determined for each channel. For every well, one
large image was obtained that covered most of the well, excluding the edges, because focusing there
proved difficult due to the color of the plate plastic.
3.5. Computational data processing and analysis
From the first experiment, images of the scanned fields were exported in an 8-bit TTF format and
analyzed with the open-source image processing program ImageJ with the Fiji package. Six highest-
quality images were chosen for each condition for analysis. When needed, visible particles that were not
cells (e.g., dust particles, fibers) were manually deleted from the images. Macroinstructions, or macros,
were used for automated analysis (the commands can be found in Appendix B). Firstly, a macro for the
channel 1 image was used to identify all the nuclei in an image. This created a mask that was then applied
to the channel 2 and channel 3 images. After running the first macro, a macro for the channel 2 image
was used to determine how many nuclei from the ones identified in channel 1 displayed DNA damage.
Then, macros for the channel 3 images (separate macros for Ki67 and cCasp3) were applied in order to
determine how many nuclei from channel 1 were positive for markers of proliferation and apoptosis,
respectively. After using the macros for each channel, the software reported the number of the identified
objects in each channel in the form of a pop-up table. The data from the table were copied onto a
Microsoft Excel spreadsheet.
From data entered into the Excel spreadsheet, the following calculations were performed. First, the
percentage of nuclei marked with γH2AX, Ki67, or cCasp3 out of all nuclei (as identified by Hoechst)
was calculated. Then, averages and confidence intervals (CIs) for all four markers were calculated for
each set of six images that were included for each condition using Excel functions, “AVERAGE” and
“CONFIDENCE”, respectively, while standard deviation necessary for CI calculation was found using
Excel function “STEDV.S”.
From the second and third experiments, images were analyzed with the analysis module installed in
ImageXpress Pico. Two protocols were created for the two double stainings. The variable settings
included segmentation parameters, namely, intensity, minimum width and maximum width values in all
three channels. Additionally, channels 2 and 3 had scoring parameters, namely the cellular part that had
been stained, and the minimum stained area value. The program then counted the nuclei present in the
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scanned area for every channel, and also calculated their percentage, like when processing the data from
the first experiment. Since every well had a replicate well, the wells that happened to have large trash
objects like fibers or dust particles mistakenly recognized as nuclei were excluded from the analysis.
When both duplicate wells had issues and neither could be used, the scoring was done manually with
ImageJ+Fiji using only high-quality areas of the wells and analyzing at least close to 200 nuclei per
condition. In addition, manual scoring was performed for all γH2AX images in the third experiment,
because the Pico analysis module did not work equally well in both γH2AX staining combinations.
The data collected with the Pico analysis module were downloaded as comma-separated values (CSV)
files which were then converted to XLSX format using an online tool and processed with Microsoft
Excel. When both replicate wells were used in the analysis, averages and CIs were calculated using Excel
functions, “AVERAGE” and “CONFIDENCE”, respectively. In the cases when only one well could be
used, no average and CI calculations could be performed. In the manual scoring, both duplicate wells
were used, so it was possible to perform average and CI calculations.
The data from all experiments were transformed into bar charts that illustrated how the numbers of
nuclei with DNA damage (γH2AX), the numbers of proliferating nuclei (Ki67), and the numbers of
apoptotic nuclei (cCasp3) were affected by increasing metformin concentrations, treatment duration, and
in the case of the third experiment, exposure to irradiation. The data was also pooled when possible and
turned into bar charts as well. When pooling the data, even though the treatment durations slightly varied
between the experiments, for simplification and convenience purposes, three major treatment duration
groups were created: i) the first group contained 24h treatment and 24h+no IR+4h treatment; ii) the
second group included 48h treatment, 48h+no IR+4h treatment, and 24h+no IR+24h treatment; iii) the
third group consisted of 72h treatment and 48h+no IR+24h treatment. Finally, statistical significance was
evaluated with Fisher’s exact two-tailed test using an online calculator: results at each lower metformin
concentration were compared with results at every higher metformin concentration, and results of shorter
metformin treatments at specific metformin concentration were compared with results of longer
metformin treatments at the same metformin concentration.
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4. RESULTS
This section briefly describes the main results from the three separate experiments and gives an
overview of the pooled data. The pooled data presented in this section is comprised of only the most
common metformin concentrations used throughout the experimental part in order to provide more
comparable and informative data, considering that not all experiments were performed under the same
conditions (e.g., short-term / long-term culture differences, different image acquisition and processing
methods). For reviewing full pooled data, please refer to Appendix D. Also note that the first experiment
has only data from Kuramochi cells, because not enough of OVCAR4 cells survived the experiment.
The purpose of the first and second experiments was to test a range of various metformin
concentrations and metformin treatment durations in order to examine whether metformin alone can
cause DNA damage and apoptosis in Kuramochi and OVCAR4 cells and influence their proliferation, as
well as to find the most suitable metformin conditions for the third experiment involving IR. These initial
metformin concentrations and treatment lengths were chosen based on previously published articles
related to metformin, ovarian cancer, and observed proliferation-inhibitory, apoptosis-inducing, cell
viability-decreasing, and similar metformin effects (Gotlieb et al., 2008; Rattan et al., 2011a; Shank et
al., 2012; Wu et al., 2012; Lengyel et al., 2015; Patel et al., 2015; Dos Santos Guimarães et al., 2018;
Yang et al., 2019). The purpose of the third experiment was to test whether any of the refined metformin
pre-treatment conditions prior to IR has an effect on recovery from IR-induced DNA damage in
Kuramochi and OVCAR4 cells. For this final experiment, it was decided to include a few higher as well
as lower metformin concentrations from the tested range, in order to have both harsher conditions and
milder ones that would better resemble physiological conditions.
4.1. γH2AX results
Upon DNA damage, namely DSBs, the histone variant H2AX is phosphorylated (Kuo et al., 2008).
Thus, the phosphorylated form, γH2AX, can be exploited as a marker for DSB detection by using an
antibody against it. Throughout the experiments, the antibody against γH2AX was used in two separate
staining combinations: γH2AX+Ki67 and γH2AX+cCasp3. γH2AX results were consistent between the
two stainings (see Appendix C) and for this reason, γH2AX data (in a form of means as percentages)
from these separately performed stainings were combined.
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In the first experiment (figure 4), among the untreated control Kuramochi cells (i.e., 0 mM
metformin), 35 ± 7 % of analyzed nuclei displayed DNA damage 24 hours, 50 ± 4 % 48 hours, and 34 ±
4 % 72 hours after seeding (figure 3, A). Overall, the lower metformin concentrations, i.e., 0,5 mM and
5 mM did not have a meaningful effect in the quantities of the γH2AX-marked Kuramochi nuclei.
Changes were visible using only the highest metformin concentration, i.e., 25 mM, in the 24h and 72h
treatments, but statistical significance was not reached in the 48h treatment (62 ± 11 %; p = 0,0829,
_____
Figure 3. Immunofluorescence images of Kuramochi cells in the first experiment: left – all nuclei in a part
of a field as identified with Hoechst; right – γH2AX-positive nuclei in the same part of the field. A: 72h plate,
0 mM metformin. B: 72h plate, 25 mM metformin. Green arrows mark γH2AX-positive nuclei.
A
B
γH2AXHoechst
Hoechst γH2AX
25
compared to controls). In the 24h treatment, this 25 mM metformin concentration resulted in 57 ± 12 %
of nuclei exhibiting DNA damage (p = 0,0079, compared to controls), and 62 ± 14 % in the 72h treatment
(p < 0,0001, compared to controls) (figure 3, B).
Figure 4. γH2AX results combined from γH2AX+Ki67 and γH2AX+cCasp3 staining combinations from
Kuramochi cells in the first experiment. 24 h refers to 24h metformin treatment, 48 h refers to 48h metformin
treatment, 72 h refers to 72h metformin treatment. Horizontal gray brackets mark statistically significant changes
in DNA damage (p < 0,05).
Results from the second experiment (figure 7) showed a general tendency of Kuramochi cells to
slightly increasingly accumulate DNA damage with increasing metformin concentrations in both
treatment durations, especially with 48h treatment  (24h treatment: p < 0,0001 for 0 mM vs. 5 mM, and
10 mM vs. 15 mM; 48h treatment: p < 0,0001 for 0 mM vs. 5 mM, 5 mM vs. 10 mM, 10 mM vs. 15 mM,
and 15 mM vs. 20 mM). Only 5 mM vs. 10 mM and 15 mM vs. 20 mM in the 24h treatment did not
follow this tendency. Using the highest (i.e., 20 mM) metformin concentration, the difference between
accumulated DNA damage compared to controls was 69 ± 7 % of nuclei versus 51 ± 6 % of nuclei in the
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24h treatment, and 69 ± 4 % versus 38 ± 2 % in the 48h treatment (figure 5) (p < 0,0001 for both).
OVCAR4 cells, on the other hand, were more resistant to metformin. Only the higher metformin
concentrations, i.e., 15 mM and 20 mM, increased DNA damage (24h and 48h treatment: p < 0,0001 for
0 mM vs. 15 mM, and 0 mM vs. 20 mM). With 20 mM metformin, 74 ± 9 % of nuclei exhibited DNA
damage compared to 63 ± 2 % of nuclei in the control group in the 24h treatment, and respectively, 55 ±
5 % compared to 39 ± 4 % in the 48h treatment (figure 6). Also, generally, more DNA damage was
visible in the 24h treatment compared to the 48h treatment, particularly in OVCAR4 cells. Since it was
also visible in controls (no metformin), it is possible that the reason for this was adverse cell reaction to
plating (i.e., being moved from one growth condition to another). Cells had more time to recover from
this procedure in the 48h treatment, and this could be why they displayed less DNA damage.
Figure 5. Immunofluorescence images of Kuramochi cells in the second experiment: left side – all nuclei in
a part of a field as identified with Hoechst; right side – γH2AX-positive nuclei in the same part of the field.
A: 48h plate, 0 mM metformin. B: 48h plate, 20 mM metformin. Green arrows mark γH2AX-positive nuclei.
A
B
Hoechst γH2AX
Hoechst γH2AX
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Figure 6. Immunofluorescence images of OVCAR4 cells in the second experiment: left side – all nuclei in a
part of a field as identified with Hoechst; right side – γH2AX-positive nuclei in the same part of the field.
A: 48h plate, 0 mM metformin. B: 48h plate, 20 mM metformin. Green arrows mark γH2AX-positive nuclei.
A
B
Hoechst γH2AX
Hoechst γH2AX
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Figure 7. γH2AX results combined from γH2AX+Ki67 and γH2AX+cCasp3 staining combinations from
Kuramochi cells (A) and OVCAR4 cells (B) in the second experiment. 24 h refers to 24h metformin treatment,
48 h refers to 48h metformin treatment. Gray text fields indicate statistically significant changes in DNA damage
(p < 0,05).
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The third experiment had a different setup than the other two experiments: it started with metformin
pre-treatment (for either 24 hours or 48 hours), followed by IR and subsequent incubation (for either 4
hours or 24 hours), in order to examine whether metformin impedes the recovery from DNA damage
caused by IR; half of the plates, however, were not affected with IR for comparison (figure 2). The 4h
post-IR incubation time point was selected, because γH2AX then is at its highest point, which is useful
for assessing whether IR was successful in inducing DNA damage, as well as for having the starting
point at its maximum value for comparison purposes (i.e., with the other time point). The 24h post-IR
incubation time point was chosen in order to examine if cells can recover from the IR-induced DNA
damage under the influence of metformin when given a substantial amount of time.
In this third experiment, non-irradiated cells produced similar DNA damage results in 24h+no IR+4h
vs. 24h+no IR+24h and 48h+no IR+4h vs. 48h+no IR+24h treatments (figure 10). Generally, Kuramochi
cells very slightly and almost gradually accumulated more DNA damage with increasing metformin
concentrations in the 48h treatments. However, in the 24h treatments, statistical significance was reached
only between 20 mM and 0 mM / 0,5 mM / 5 mM / 10 mM (24h+no IR+4h treatment), or only between
20 mM and 0 mM, as well as 10 mM and 0 mM (24h+no IR+24h treatment). In all cases, the highest
metformin concentration, i.e., 20 mM, was the most effective in inducing DNA damage: 61 ± 3 % of
nuclei were marked with γH2AX at 20 mM compared to 46 ± 5 % of nuclei at 0 mM in the 24h+no
IR+4h treatment (p < 0,0001), and respectively, 59 ± 3 % compared to 42 ± 6 % in the 48h+no IR+4h
treatment (p < 0,0001), 53 ± 4 % compared to 43 ± 5 % in the 24h+no IR+24h treatment (p = 0,0034),
and 58 ± 2 % compared to 38 ± 2 % in the 48h+no IR+24h treatment (p < 0,0001) (figure 8). In
comparison, γH2AX positivity in OVCAR4 cells was mostly unaffected by metformin. There was only
a slight increase in DNA damage with the highest metformin concentration (20 mM) in the longest
treatment duration (48h+no IR+24h) going from 42 ± 6 % of nuclei with DNA damage at 0 mM to 47 ±
2 % at 20 mM (p = 0,0190) (figure 9).
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Figure 8. Immunofluorescence images of Kuramochi cells in the no IR part of the third experiment: left
side – all nuclei in a part of a field as identified with Hoechst; right side – γH2AX-positive nuclei in the same
part of the field. A: 48h+no IR+24h plate, 0 mM metformin. B: 48h+no IR+24h plate, 20 mM. Green arrows
mark γH2AX-positive nuclei.
A
B
Hoechst γH2AX
Hoechst γH2AX
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Figure 9. Immunofluorescence images of OVCAR4 cells in the no IR part of the third experiment: left side
– all nuclei in a part of a field as identified with Hoechst; right side – γH2AX-positive nuclei in the same
part of the field. A: 48h+no IR+24h plate, 0 mM metformin. B: 48h+no IR+24h plate, 20 mM. Green arrows
mark γH2AX-positive nuclei.
Figure 10. γH2AX results combined from γH2AX+Ki67 and γH2AX+cCasp3 staining combinations from
Kuramochi cells in the no IR+4h (A) and the no IR+24h (C) parts of the third experiment, and from
OVCAR4 cells in the no IR+4h (B) and the no IR+24h (D) parts of the third experiment. Legends indicate
metformin treatment durations. Horizontal gray brackets mark statistically significant changes in DNA damage (p
< 0,05).
B
A
Hoechst γH2AX
Hoechst γH2AX
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After pooling the data from all experimental parts that did not include irradiation (figure 11), it is
visible that tested metformin treatment durations overall did not have much an effect on DNA damage,
but concentrations mattered. Kuramochi cells experienced a substantial increase in DNA damage with ≥
10 mM metformin solutions in all treatment lengths (p < 0,0001), whereas OVCAR4 responded to as
high as 20 mM concentration of metformin (p ≤ 0,0190) and only marginally. Metformin concentration
of 20 mM increased the percentage of Kuramochi nuclei with DNA damage from 39 ± 6 % at 0 mM to
65 ± 4 % at 20 mM in the 24h treatment group, and respectively, from 45 ± 3 % to 60 ± 4 % in the 48h
treatment group, and from 35 ± 3 % to 58 ± 2 % in the 72h treatment group. The same metformin
concentration raised the percentage of OVCAR4 nuclei with DNA damage from 49 ± 9 % at 0 mM to 59
± 12 % at 20 mM in the 24h treatment group, and respectively, from 44 ± 2 % to 49 ± 3 % in the 48h
treatment group, and from 42 ± 6 % to 47 ± 2 % in the 72h treatment group.
Figure 11. Pooled γH2AX results from all non-irradiated Kuramochi (A) and OVCAR4 (B) cells. Legends
indicate metformin treatment duration groups. Gray text fields indicate statistically significant changes in DNA
damage (p < 0,05).
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Irradiated cells in the third experiment displayed high amounts of DNA damage when 4 hours had
passed since irradiation (figure 14), as expected, because repair was still ongoing at this time point.
Nearly 100% of nuclei exhibited DNA damage in both cell lines and all metformin treatment conditions
including controls (figures 12-13), indicating that irradiation successfully induced DNA damage in
effectively all cells.
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72h treatment group at every concentration except for 0 mM and 0,5 mM.
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Figure 12. Immunofluorescence images of Kuramochi cells in the IR+4h part of the third experiment: left
side – all nuclei in a part of a field as identified with Hoechst; right side – γH2AX-positive nuclei in the same
part of the field. A: 48h+IR+4h plate, 0 mM metformin. B: 48h+IR+4h plate, 20 mM metformin. All nuclei on
the right-side panels can be considered as γH2AX-positive.
A
B
Hoechst
Hoechst
γH2AX
γH2AX
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Figure 13. Immunofluorescence images of OVCAR4 cells in the IR+4h part of the third experiment: left
side – all nuclei in a part of a field as identified with Hoechst; right side – γH2AX-positive nuclei in the same
part of the field. A: 48h+IR+4h plate, 0 mM metformin. B: 48h+IR+4h plate, 20 mM metformin. All nuclei on
the right-side panels can be considered as γH2AX-positive.
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B
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Hoechst
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Figure 14. γH2AX results combined from γH2AX+Ki67 and γH2AX+cCasp3 staining combinations used
for Kuramochi (A) and OVCAR4 (B) cells in the IR+4h part of the third experiment. Legends indicate
metformin treatment durations. Horizontal gray brackets mark statistically significant changes in DNA damage (p
< 0,05).
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When 24 hours had passed after irradiation (figure 17), Kuramochi cells still had high amounts of
DNA damage: around 90% of nuclei were marked with γH2AX, and slightly more nuclei were affected
in higher metformin concentrations, particularly 20 mM (the highest concentration used) (p < 0,0001,
______
Figure 15. Immunofluorescence images of Kuramochi cells in the IR+24h part of the third experiment: left
side – all nuclei in a part of a field as identified with Hoechst; right side – γH2AX-positive nuclei in the same
part of the field. A: 48h+IR+24h plate, 0 mM metformin. B: 48h+IR+24h plate, 20 mM metformin. Gray arrows
mark γH2AX-negative nuclei.
A
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compared to controls, both 24h and 48h treatments) (figure 15). However, OVCAR4 cells in control
wells and wells containing lower metformin concentrations exhibited considerably less DNA damage:
around 60-70% of nuclei were marked with γH2AX in the 0-10 mM metformin concentration range.
Nevertheless, the highest metformin concentration (20 mM) resulted in an elevated percentage of nuclei
with persistent damage, 81 ± 4 % in the 24h treatment, and even 94 ± 5 % in the longer, 48h treatment
(figure 16). These increases when compared to controls (i.e., 67 ± 4 % in the 24h treatment, and 75 ± 4
% in the 48h treatment) were statistically significant (p < 0,0001).
Figure 16. Immunofluorescence images of OVCAR4 cells in the IR+24h part of the third experiment: left
side – all nuclei in a part of a field as identified with Hoechst; right side – γH2AX-positive nuclei in the same
part of the field. A: 48h+IR+24h plate, 0 mM metformin. B: 48h+IR+24h plate, 20 mM metformin. Gray arrows
mark γH2AX-negative nuclei; the absence of arrows indicates that all nuclei are γH2AX-positive.
B
Hoechst γH2AX
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Hoechst γH2AX
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Figure 17. γH2AX results combined from γH2AX+Ki67 and γH2AX+cCasp3 staining combinations used
for Kuramochi (A) and OVCAR4 (B) cells in the IR+24h part of the third experiment. Legends indicate
metformin treatment durations. Gray text fields indicate statistically significant changes in DNA damage (p <
0,05).
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4.2. Ki67 results
A primary antibody against Ki67 is an extensively used marker for assessing cell proliferation (Li et
al., 2015). Ki67 is a nuclear protein whose elevated expression has been associated with malignant cell
proliferation, making it also useful for cancer diagnosis and prognosis (Li et al., 2015).
In the first experiment (figure 19), only the highest metformin concentration, i.e., 25 mM visibly
reduced proliferation of Kuramochi cells in all three treatment durations. This is in accordance with DNA
damage data from this experiment, where only this highest metformin concentration was effective as
well. In the 24h treatment, 45 ± 23 % of nuclei were Ki67-positive in the 25 mM metformin concentration
compared to 67 ± 3 % of nuclei in controls (p < 0,0001), 36 ± 15 % compared to 68 ± 9 % in the 48h
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mM vs. 20 mM (both treatments), 24h+IR+24h vs. 48h+IR+24h at 0 mM and 20 mM.
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treatment (p < 0,0001) (figure 18), and 48 ± 24 % compared to 56 ± 11 % in the 72h treatment (p =
0,0448).
Figure 18. Immunofluorescence images of Kuramochi cells in the first experiment: left – all nuclei in a part
of a field as identified with Hoechst; right – Ki67-positive nuclei in the same part of the field. A: 48h plate, 0
mM metformin. B: 48h plate, 25 mM metformin. Red arrows mark Ki67-positive nuclei.
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Figure 19. Ki67 results from Kuramochi cells used in the first experiment. 24 h refers to 24h metformin
treatment, 48 h refers to 48h metformin treatment, 72 h refers to 72h metformin treatment. Horizontal gray brackets
mark statistically significant changes in proliferation (p < 0,05).
In the second experiment (figure 22), proliferation did not change much with the varying metformin
concentrations and treatment durations, but OVCAR4 cells proliferated significantly less than
Kuramochi cells. Nevertheless, there was a slight reduction in Kuramochi proliferation in the presence
of metformin, compared to controls with no metformin in both treatment durations. In the 24h treatment,
all used metformin concentrations produced similar results which were only marginally, but statistically
significantly (p ≤ 0,0004) different from controls. The highest metformin concentration (i.e., 20 mM)
resulted in 78 ± 4 % of nuclei being marked for proliferation as compared to 84 % (no CI obtained due
to one of the duplicate wells being unsuitable for analysis) of nuclei that were not treated with metformin
(p < 0,0001). The 48h treatment displayed more a trend of gradually reduced Kuramochi proliferation
with increasing metformin concentration, starting with 10 mM (p < 0,0001 for 0 mM vs. 5 mM / 10 mM,
10 mM vs. 15 mM, and 15 mM vs. 20 mM). The highest, i.e., 20 mM concentration considerably reduced
Kuramochi proliferation from 85 ± 1 % (in controls) to 69 ± 4 % (p < 0,0001) (figure 20). OVCAR4
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cells, again, were more resistant to metformin, and only the highest metformin concentration (i.e., 20
mM) and the longest treatment duration (i.e., 48h) slightly decreased proliferation from 50 % (no CI
obtained due to one of the duplicate wells being unsuitable for analysis) (in controls) to 43 ± 1 % (p <
0,0001) (figure 21).
Figure 20. Immunofluorescence images of Kuramochi cells in the second experiment: left side – all nuclei
in a part of a field as identified with Hoechst; right side – Ki67-positive nuclei in the same part of the field.
A: 48h plate, 0 mM metformin. B: 48h plate, 20 mM metformin. Red arrows mark Ki67-positive nuclei.
B
A
Hoechst Ki67
Hoechst Ki67
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Figure 21. Immunofluorescence images of OVCAR4 cells in the second experiment: left side – all nuclei in
a part of a field as identified with Hoechst; right side – Ki67-positive nuclei in the same part of the field. A:
48h plate, 0 mM metformin. B: 48h plate, 20 mM metformin. Red arrows mark Ki67-positive nuclei.
Figure 22. Ki67 results from Kuramochi (A) and OVCAR4 (B) cells used in the second experiment. 24 h
refers to 24h metformin treatment, 48 h refers to 48h metformin treatment. Gray text fields indicate statistically
significant changes in proliferation (p < 0,05).
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In the third experiment (figure 25), non-irradiated Kuramochi cells did not display substantial changes
in the percentage of Ki67-positive nuclei numbers with the different metformin concentrations, as
compared to controls except for slightly reduced proliferation using 20 mM metformin (i.e., the highest
concentration) in the 48h+no IR+4h treatment (from 75 ± 11 % to 68 ± 4 %), the 24h+no IR+24h
treatment (from 83 ± 4 % to 74 ± 7 %), and the 48h+no IR+24h treatment (from 64 ± 2 % to 61 ± 2 %)
(figure 23) (p < 0,0001 for all). Also, Kuramochi cells in the longest treatment, i.e., 48h+no IR+24h,
proliferated to a smaller extent compared to the other treatments. Non-irradiated OVCAR cells in general
Figure 23. Immunofluorescence images of Kuramochi cells in the no IR part of the third experiment: left
side – all nuclei in a part of a field as identified with Hoechst; right side – Ki67-positive nuclei in the same
part of the field. A: 48h+no IR+24h plate, 0 mM metformin. B: 48h+no IR+24h plate, 20 mM. Red arrows mark
Ki67-positive nuclei.
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proliferated less than Kuramochi cells, which is in line with the data from the second experiment. Also,
notable decreases of OVCAR4 proliferation were observed at the same conditions as in the cases of
Kuramochi proliferation in this third experiment: 63 ± 1 % of nuclei were marked for proliferation at 0
mM as opposed to 43 ± 1 % of nuclei at 20 mM in the 48h+no IR+4h treatment, and respectively, 53 ±
1 % compared to 45 ± 4 % in the 24h+no IR+24h treatment, and 58 ± 3 % compared to 44 ± 5 % in the
48h+no IR+24h treatment (figure 24) (p < 0,0001 for all).
Figure 24. Immunofluorescence images of OVCAR4 cells in the no IR part of the third experiment: left side
– all nuclei in a part of a field as identified with Hoechst; right side – Ki67-positive nuclei in the same part
of the field. A: 48h+no IR+24h plate, 0 mM metformin. B: 48h+no IR+24h plate, 20 mM. Red arrows mark Ki67-
positive nuclei.
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Figure 25. Ki67 results from Kuramochi cells in the no IR+4h (A) and the no IR+24h (C) parts of the third
experiment, and from OVCAR4 cells in the no IR+4h (B) and the no IR+24h (D) parts of the third
experiment. Legends indicate metformin treatment durations. Gray text fields indicate statistically significant
changes in proliferation (p < 0,05).
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In the pooled data from all non-irradiated cells used in the three experiments (figure 26), the highest
(20 mM) metformin concentration was effective in slightly reducing Kuramochi proliferation only in the
48h treatment group from 75 ± 6 % of Ki67-positive nuclei at 0 mM to 70 ± 3 % of nuclei at 20 mM (p
< 0,0001). Kuramochi proliferation was overall less intense in the longer, 72h treatment group compared
to proliferation in the shorter treatment groups, but proliferation results at 20 mM metformin were not
very different from controls. Compared to Kuramochi proliferation, OVCAR4 proliferation was slightly
lower across all metformin concentrations (including controls) and treatment groups. Substantial
reduction in OVCAR4 proliferation was observed using 20 mM metformin in the same 48h treatment
group (just like in the case of Kuramochi proliferation), but also an additional 72h treatment duration
was just as efficient in reducing OVCAR4 proliferation: from 56 ± 5 % to 44 ± 1 % (p < 0,0001), and
from 58 ± 3 % to 44 ± 5 % (p < 0,0001), respectively. In addition, there was aberrant decrease in
OVCAR4 proliferation at 0,5 mM metformin in the 24h treatment group, from 56 ± 7 % of Ki67-positive
nuclei at 0 mM to 42 ± 7 % of nuclei at 0,5 mM (p < 0,0001). However, this result stems from one
experiment only. Therefore, it could have appeared due to chance and its reproducibility should be
checked in the future.
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Figure 26. Pooled Ki67 results from all non-irradiated Kuramochi (A) and OVCAR4 (B) cells. Legends
indicate metformin treatment duration groups. Gray text fields indicate statistically significant changes in
proliferation (p < 0,05).
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Considering data from the post-metformin irradiation experiments, 4h after irradiation time point
(figure 29) generally gave proliferation results similar to those seen in the non-irradiated cells. At first
sight, this result is a bit unexpected, since IR-induced unrepaired damage should theoretically halt
proliferation. This matter is reviewed in more detail in Discussion. The highest metformin concentration,
i.e., 20 mM was the only one able to visibly reduce Kuramochi proliferation in both 24h+IR+4h and
48h+IR+4h treatments, decreasing the proportions of Ki67-positive nuclei from 80 ± 1 % at 0 mM to 67
± 6 % at 20 mM (p < 0,0001) (figure 27), and from 75 ± 8 % at 0 mM to 71 ± 0,4 % at 20 mM (p <
0,0001), respectively. In addition, 10 mM metformin concentration reduced Kuramochi proliferation in
the 24h+IR+4h treatment with enough statistical significance (p < 0,0001), but the decrease was modest:
from 80 ± 1 % at 0 mM to 76 ± 7 % at 10 mM. In comparison, OVCAR4 cells experienced a reduction
in proliferation only in the longer treatment, the 48h+IR+4h time point, going from 63 ± 1 % of nuclei
marked for proliferation at 0 mM to 43 ± 6 % of nuclei at 20 mM (p < 0,0001) (figure 28). However, in
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group vs. 48h treatment group at 5 mM, 24h treatment group vs. 72h treatment group at 0 mM and 10 mM, and 48h
treatment group vs. 72h treatment group at 0 mM, 5 mM, 10 mM, and 20 mM.
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addition to 20 mM metformin concentration, 10 mM was also efficient in this treatment duration for
OVCAR4 cells, as well as 5 mM although to a much smaller extent, decreasing the proliferating nuclei
portion to 48 ± 0,1 % (p < 0,0001), and 59 ± 9 % (p < 0,0028), respectively. Finally, there was an
irregularity in OVCAR4 proliferation results at 0,5 mM in the 24h+IR+4h treatment, where the portion
of Ki67-marked nuclei drastically diminished from 46 ± 1 % to 32 ± 1 % (p < 0,0001), but increased
____
Figure 27. Immunofluorescence images of Kuramochi cells in the IR+4h part of the third experiment: left
side – all nuclei in a part of a field as identified with Hoechst; right side – Ki67-positive nuclei in the same
part of the field. A: 24h+IR+4h plate, 0 mM metformin. B: 24h+IR+4h plate, 20 mM metformin. Red arrows
mark Ki67-positive nuclei.
A
B
Hoechst Ki67
Hoechst Ki67
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again at higher metformin concentrations. Since this effect was not visible in the 48h+IR+4h treatment,
it could be a sporadic event, and performing more experiments like this could be beneficial in order to
determine whether such a result is reproducible.
Figure 28. Immunofluorescence images of OVCAR4 cells in the IR+4h part of the third experiment: left
side – all nuclei in a part of a field as identified with Hoechst; right side – Ki67-positive nuclei in the same
part of the field. A: 48h+IR+4h plate, 0 mM metformin. B: 48h+IR+4h plate, 20 mM metformin. Red arrows
mark Ki67-positive nuclei.
Figure 29. Ki67 results from Kuramochi (A) and OVCAR4 (B) cells in the IR+4h part of the third
experiment. Legends indicate metformin treatment durations. Gray text fields indicate statistically significant
changes in proliferation (p < 0,05).
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Note: All changes are statistically significant (p < 0,05) except for 0 mM vs. 10 mM / 20 mM and 10
mM vs. 20 mM in the 24h+IR+4h treatment, 0 mM vs. 0,5 mM in the 48h+IR+4h treatment, and
24h+IR+4h treatment vs. 48h+IR+4h treatment at 10 mM.
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When 24 hours had passed since irradiation (figure 32), Kuramochi proliferation rates were similar to
the ones seen at the earlier time point, but only in the shorter, 24h+IR+24h treatment, where only 20 mM
metformin concentration was effective again, reducing the proliferating nuclei portion from 83 ± 1 % at
0 mM to 69 ± 5 % at 20 mM (p < 0,0001) (figure 30). The longer, 48h+IR+24h treatment resulted in
overall considerably diminished Kuramochi proliferation, but the part of Ki67-marked nuclei remained
virtually the same between controls and the different metformin concentrations, around 60 %. Finally,
___
Figure 30. Immunofluorescence images of Kuramochi cells in the IR+24h part of the third experiment: left
side – all nuclei in a part of a field as identified with Hoechst; right side – Ki67-positive nuclei in the same
part of the field. A: 24h+IR+24h plate, 0 mM metformin. B: 24h+IR+24h plate, 20 mM metformin. Red arrows
mark Ki67-positive nuclei.
A
B
Hoechst Ki67
Hoechst Ki67
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OVCAR4 cells proliferated considerably more at this 24h after irradiation time point compared to the 4h
after irradiation time point, and the numbers of proliferating nuclei were similar in controls and at lower
metformin concentrations. However, the highest metformin concentration, i.e., 20 mM successfully
managed to weaken OVCAR4 proliferation ability, trimming the proliferating nuclei fraction from 64 ±
1 % at 0 mM to 58 ± 2 % at 20 mM in the 24h+IR+24h treatment (p < 0,0001), and from 78 ± 5 % at 0
mM to a drastic number of just 39 ± 7 % at 20 mM in the 48h+IR+24h treatment (p < 0,0001) (figure
31).
Figure 31. Immunofluorescence images of OVCAR4 cells in the IR+24h part of the third experiment: left
side – all nuclei in a part of a field as identified with Hoechst; right side – Ki67-positive nuclei in the same
part of the field. A: 48h+IR+24h plate, 0 mM metformin. B: 48h+IR+24h plate, 20 mM. Red arrows mark Ki67-
positive nuclei.
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Figure 32. Ki67 results from Kuramochi (A) and OVCAR4 (B) cells in the IR+24h part of the third
experiment. Legends indicate metformin treatment durations. Gray text fields indicate statistically significant
changes in proliferation (p < 0,05).
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4.3. cCasp3 results
Caspase 3 is a pivotal executioner caspase that can be activated by any of the initiator caspases (i.e.,
caspases 8-10) participating in the different apoptotic pathways (Elmore, 2007). Activation prompts
cleavage, and the cleaved caspase 3 (or, cCasp3) cleaves, activates, and inactivates various proteins that
partake in apoptotic events resulting in morphological and biochemical alterations characteristic to
apoptotic cells (Elmore, 2007; Al-Hassan et al., 2019). Being one of the hallmarks of apoptosis, cCasp3
is utilized in apoptosis detection (Elmore, 2007; Meng et al., 2018). In this study, cCasp3 was assessed
by using a primary antibody against it.
Figure 34 contains a bar chart with cCasp3 results. There is only one set of data, from Kuramochi
cells that survived the first experiment. In this data set, only the highest metformin concentration, i.e., 25
mM significantly increased apoptosis in all three treatment durations. In the 24h treatment, 63 ± 9 % of
nuclei were marked for apoptosis at the 25 mM metformin concentration compared to 52 ± 18 % of nuclei
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in controls, and respectively, 97 ± 4 % compared to 35 ± 18 % in the 48h treatment, and 76 ± 14 %
compared to 14 ± 12 % in the 72h treatment (figure 33) (p < 0,0001 for all). However, 5 mM metformin
concentration in the 48h treatment, as well as 0,5 mM and 5 mM metformin concentrations in the 72h
treatment also increased apoptosis compared to controls, although these increases were modest: from 35
± 18 % of cCasp3-marked nuclei at 0 mM to 41 ± 21 % at 5 mM in the 48h treatment, from 14 ± 12 %
__
Figure 33. Immunofluorescence images of Kuramochi cells in the first experiment: left – all nuclei in a part
of a field as identified with Hoechst; right – cCasp3-positive nuclei in the same part of the field. A: 72h plate,
0 mM metformin. B: 72h plate, 25 mM metformin. Yellow arrows mark cCasp3-positive nuclei.
A
B
Hoechst cCasp3
Hoechst cCasp3
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at 0 mM to 27 ± 10 % at 0,5 mM and to 24 ± 12 % at 5 mM in the 72h treatment (p < 0,0001 for all).
Interestingly, there was a slight variation in apoptotic nuclei numbers between different treatment
durations: the 24h metformin treatment produced the most apoptotic nuclei in controls and lower
metformin concentrations (i.e., 0 mM, 0,5 mM, and 5 mM), but the least apoptotic nuclei in the highest
metformin concentration (i.e., 25 mM), and the 48h metformin treatment was slightly more effective in
inducing apoptosis in all metformin concentrations and controls than the 72h treatment. The decreasing
trend with time in the 0-5 mM range could be due to the shock caused to the cells by thawing the ampule
shortly before plating. The effect could still be visible at the 24h time point, but then later cells appeared
to recover from it. The lower metformin concentrations do not seem to have a large effect, so cells may
react in a more similar trend as controls do, but when metformin concentration is high enough to be
profoundly effective, longer treatments give rise to more apoptosis.
Figure 34. cCasp3 results from Kuramochi cells used in the first experiment. 24 h refers to 24h metformin
treatment, 48 h refers to 48h metformin treatment, 72 h refers to 72h metformin treatment. The gray text field
indicates statistically significant changes in apoptosis (p < 0,05).
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There are no substantial cCasp3 data from the second and third experiments. In roughly 1000 analyzed
nuclei per field, only a couple or a few were marked for apoptosis. Figure 35 illustrates this absence of
apoptotic nuclei.
Figure 35. Immunofluorescence images from the second and third experiments: left – all nuclei in a part of
a field as identified with Hoechst; right – cCasp3-positive nuclei in the same part of the field. A: Kuramochi,
48h plate, 15 mM metformin. B: OVCAR4, 24h+IR+4h plate, 10 mM metformin. The nuclei lack cCasp3
positivity as well as apoptotic properties like blebbing and nuclear fragmentation.
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5. DISCUSSION
Several studies have described the association between metformin intake and improved survival rate
in diabetic ovarian cancer patients, as well as metformin’s anti-proliferative and pro-apoptotic effects on
various cancer, including ovarian cancer, cells. However, there was a lack of comprehensive data and
understanding about metformin effect on DNA damage in HGSOC cells, particularly with regards to HR.
It is important to take into consideration the HR status of analyzed HGSOC cells, because HR proficiency
is known to determine chemo-resistance, while HR deficiency correlates with better prognosis and
improved survival.
This study aimed to test what kind of an effect different metformin concentrations and treatment
lengths have with and without IR on DNA damage, as well as proliferation and apoptosis in two HGSOC
cell lines of different HR status: Kuramochi, which is an HR-deficient cell line, and OVCAR4, an HR-
proficient cell line. Cells were exposed to metformin (0,5-25 mM) and incubated for 24-72 hours, and a
part of cells was additionally irradiated after the metformin pre-treatment, followed by incubation for 4
or 24 more hours (figure 2). After that, cells were fixed, stained, and imaged. Finally, the acquired data
were processed (including pooling, when possible) and analyzed. This study has found that the highest
used metformin concentrations give the most substantial results with regards to increasing DNA damage,
decreasing proliferation, and increasing apoptosis, and that sometimes only longer treatments (48h and
72h treatment) give a desirable effect, especially considering proliferation. OVCAR4 cell line was found
to be more resistant to metformin treatment than Kuramochi cell line, but high metformin concentrations
(such as 20 mM) and longer treatments coupled with IR very efficiently increased DNA damage and
reduced proliferation even for this HR-proficient cell line (no data was obtained on apoptosis though).
Although this study examined just two ovarian cancer cell lines, it still contributes to the cause of
obtaining more information about metformin impact on DNA damage in ovarian cancer – a matter on
which the previously existing knowledge was very scarce and incomplete. Moreover, to our knowledge,
this is the first study that investigated metformin effects on DNA damage, as well as proliferation and
apoptosis in HGSOC cell lines while taking into consideration their HR status. In addition, this study
chose to use cell lines whose culture media does not require insulin, which by itself would affect results.
Metformin increases insulin uptake by sensitizing tissues to insulin, which then lowers glucose levels
(Bailey et al., 1996). Hence, both agents, in general, have the glucose-lowering effect, and having insulin
in the media would not allow proper examination of specific metformin effects. Not all previously
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performed studies took this into account (Gotlieb et al., 2008; Rattan et al., 2011a), and in this aspect,
my study provides improved accuracy for metformin-dependent cellular read-outs.
Based on the literature review, I expected the HR-proficient OVCAR4 cells to be affected by
metformin with regards to increased DNA damage, reduced proliferation, and increased apoptosis.
Several metformin concentrations and treatment durations were selected in order to test this idea, also
based on what could be found in previous publications. When the highest chosen metformin
concentration in the first experiment, i.e., 25 mM killed many cells, and OVCAR4 cells essentially did
not survive that whole experiment (see also Appendix E), it was decided to lower the metformin
concentration and use cells that were kept in long-term culture, with the reasoning that recent thawing,
in addition to metformin treatment, might cause too big of a shock to cells. The long-term culture aspect
proved to be extremely important in this experimental setup, because further experiments yielded
substantially higher numbers of cells in both cell lines, no matter how the high metformin concentration
was (see Appendix E). The highest metformin concentration in further experiments was selected to be
20 mM, and essentially, it ended up being the only significant concentration considering the study aims.
The 20 mM metformin concentration was the most effective in the HR-deficient Kuramochi cell line
in terms of changing both DNA damage and proliferation. Some lower metformin concentrations had a
noticeable effect on Kuramochi cells too, but they were overall ineffective on the HR-proficient
OVCAR4 cell line. Only 20 mM metformin increased DNA damage in both non-irradiated and irradiated
OVCAR4 cells when compared to controls (i.e., 0 mM metformin) (figure 11, B; figure 17, B). The effect
of the 20 mM concentration was particularly visible 24 hours after irradiation: at this time point, HR-
proficient OVCAR4 cells had sufficient time to repair the induced DNA damage, resulting in a decreased
percentage of nuclei with DNA damage, by roughly a third or a quarter in control wells and the wells
with lower metformin concentrations. However, the high metformin concentration (20 mM) was able to
raise this number again – in the longer treatment (48h) even close to the one seen at the 4h time point
after irradiation (over 90%) (figure 16; figure 13). The findings from the DNA damage part of the
experiment were in agreement with the findings from the proliferation part. Only 20 mM metformin
concentration reduced proliferation in non-irradiated and irradiated OVCAR4 cells (figure 26, B; figure
32, B). The most illustrative and substantial effect was observed at the 24h after irradiation time point
with the longest metformin pre-treatment (48h+IR+24h) where OVCAR4 proliferation dropped by
approximately half (figure 31).
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One more finding from γH2AX and Ki67 analyses is worth additional discussion. Interestingly, at the
4h after irradiation time point, the fractions of Ki67-positive Kuramochi and OVCAR4 nuclei were
similar to the ones seen without irradiation at corresponding metformin treatment durations and
concentrations (figure 26, figure 29). This is somewhat counter-intuitive, because one might expect the
IR-induced unrepaired damage to halt proliferation. I was unable to find suitable previous publications
to compare my findings to others, but at least at 8 hours after irradiation, another HR-deficient cell line,
OVCAR8, had only a marginal Ki67-positive nuclei percentage difference from the percentage observed
in non-irradiated cells, and another HR-proficient cell line, OVCAR3, virtually did not exhibit any
differences in proliferation between these two groups (Tumiati et al., 2018 (supplementary data)). In
addition, comparing my findings to the ones published by Tumiati et al. (2018), there were a couple of
other visible similarities in γH2AX- and Ki67-positivity trends among my tested untreated HR-deficient
and HR-proficient cell lines (Kuramochi and OVCAR4, respectively), and their examined HR-deficient
and HR-proficient cell lines (OVCAR8 and OVCAR3, respectively). For instance, in the referenced
publication, the fraction of proliferating OVCAR8 nuclei was bigger than OVCAR3 by more than a third,
which was similar to the proliferation results of my study, where I also observed higher Ki67-positive
nuclei percentages in Kuramochi cell line than in OVCAR4 cell line. Another similarity was only a slight
reduction of γH2AX positivity at 24 hours after irradiation for OVCAR8 in the referenced study and for
Kuramochi in my study, but a significant decrease in γH2AX positivity at the same time point for
OVCAR3 and OVCAR4, respectively. Even the percentages themselves in both γH2AX and Ki67
analyses did not extremely differ between these two studies among the examined corresponding HR-
deficient and HR-proficient cell lines.
However, γH2AX and Ki67 analyses in one of the experiments had a caveat of partly automated /
partly manual scoring of γH2AX- and Ki67-positive nuclei. Each well had a replicate well, but in the
unfortunate cases in the third experiment when both wells had large non-cellular objects and could not
be used for the automated scoring, manual scoring was used analyzing only the good-quality areas of the
wells. Ideally, in such a case, manual scoring should be performed in all of the wells, so that the data
would be more comparable, or both wells unsuitable for automated scoring should be excluded from the
analysis. However, in this study, I wanted to reduce the amount of missing data as much as possible, and
since manual scoring is a long process that had not been intended in the project plan considering the
length of the project, it was decided to score Ki67 manually only in the poorer-quality wells and apply
the automated scoring to the rest of the wells. In addition, it was problematic to make the software work
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equally well for the two γH2AX staining combinations in the third experiment. Therefore, γH2AX was
scored manually in this experiment – this time, in all of the wells. Appendix E marks all the cases when
manual scoring was applied.
Unfortunately, the experiments described in this thesis generated little data on apoptosis (figures 33-
34; Appendix E). Only the first experiment that used recently thawn cells yielded results, but only for
Kuramochi cells, the only ones that survived that experiment. The first experiment had a few other
problems besides the missing OVCAR4 data, such as large confidence intervals due to a rather small
number of scanned fields that were chosen randomly and contained unevenly distributed numbers of
nuclei. Also, as already mentioned, high metformin concentration (25 mM) proved to be lethal to many
recently thawn cells and it also increased confidence intervals even more. It was then decided not to
repeat that particular experiment, with the reasoning that more information would be gained with further
experiments that would also include more concentrations, and irradiation, making the data also more
informative. Nevertheless, in these further experiments, there were just a few signals of cCasp3 (figure
35) – not enough to form conclusive deductions. One possible explanation for the lack of a cCasp3 signal
is short-term culture vs. long-term culture. The first experiment used cells that had been thawed only
approximately 72 hours earlier, and thawing could cause stress, making cells more apoptotic. In contrast,
the second and third experiments used cells that had been regularly passaged, i.e., kept in long-term
culture. Therefore, they were less sensitive. Another explanation for the absence of a cCasp3 signal could
be that there was apoptosis, but perhaps it could not be detectable with this particular marker. However,
this is unlikely, because apoptotic nuclei typically have certain characteristics, mainly nuclear
fragmentation and cytoplasmic blebbing (Patel et al., 2015), which were predominantly absent in the
analyzed nuclei, even in the irradiated cells. The most likely explanation is that the selected time points
were not suitable to detect apoptosis. Ideally, after irradiation, cCasp3 should be analyzed at the 8h time
point, which was missing in these experiments. It was decided to simplify the experimental setup in order
to have fewer time points to test with the intention to detect cCasp3 signal at the 24h time point, but it is
possible that it was too late (cells either repaired the induced damage or died, but the cCasp3 signal was
missed), while the 4h time point was too early. The 24h and 48h time points in the second experiment
might have had the same fault of being unsuitable. Future experiments of this kind should certainly
include the 8h time point. Nevertheless, the obtained cCasp3 data from Kuramochi cells from the first
experiment suggest that, again, only high metformin concentrations, such as 25 mM, have the ability to
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increase apoptosis eminently. More apoptosis experiments should be performed in order to verify this,
and it is necessary to analyze an HR-proficient cell line as well.
A comparison of my metformin analysis results to the ones obtained in previous publications of similar
design brings both concordance and discrepancy. A study by Lengyel et al. (2015) did not find
Kuramochi proliferation to decrease with 10 mM metformin (MTT assay was used for assessment),
which is in agreement with my finding. In the same study, however, they found other cell lines, namely
OVCAR5, Kras/PTEN, SKOV3ip1, and Hey A8 to respond to 10 mM metformin, unlike Kuramochi. A
discrepancy example is a study by Gotlieb et al. (2008) that reported proliferation inhibition of OVCAR4
and OVCAR3 cells (which are both HR-proficient) induced by 72h metformin treatment starting already
at 1 mM, the inhibitory effect increasing with increasing metformin concentrations (up to 100 mM),
though their used analysis method was different – cell viability determination using AlamarBlue
colorimetric assay. I could not find more studies that used the same cell lines as I did. There were several
studies that analyzed SKOV3 cells, and I referred to these studies when selecting metformin conditions
for my experiments, but it is important to note that SKOV3 is not an HGSOC cell line, and metformin
effect on these cells can be very different from the ones seen in HGSOC cells. Even among these SKOV3
studies, varying results are reported. For example, a study by Shank et al. (2012) found that SKOV3
proliferation is inhibited by 3-day metformin treatment starting at 1 mM (the method of choice was cell
viability evaluation by performing cell count using trypan blue and flow cytometry). However, another
study (Patel et al., 2015) determined that SKOV3 cell viability is inhibited by applying 48h treatment
using only a range of rather high metformin concentrations, 15-30 mM (the method used was MTT
assay), which is more in line with my findings. The same study also found that 48h metformin treatment
at 15 mM prompts SKOV3 cell cycle arrest and apoptosis (from 5,1 % detected apoptosis in untreated
cells to 14,5 % in treated cells; analysis method – flow cytometry). Finally, one more study (Wu et al.,
2012) reported substantially larger inhibition of proliferation in 48h and 72h treatments using the range
of 5-50 mM metformin, compared to 24h treatment, but no apoptosis was detected in SKOV3 cells
following 24h 0-20 mM metformin treatment (for this purpose, annexin V expression was assessed using
flow cytometry).
Despite the discussed shortcomings, this study still gathered novel and scientifically valuable data on
metformin effects on two HGSOC cell lines of different HR status. Overall, my findings indicate that
HR-proficient cells, such as OVCAR4, are still able to repair induced DNA damage, survive and
proliferate when treated with lower metformin concentrations (0,5-10 mM), but become impaired when
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exposed to high metformin concentrations, such as 20 mM. This is a promising finding suggesting that
it might be possible to affect even chemo-resistant HR-proficient cell lines with appropriate metformin
concentrations. A point to consider, though, is the feasibility of delivering metformin concentrations as
high as 20 mM to the human body without causing noxious effects, in spite of metformin being a safe
and well-tolerated drug (Patel et al., 2015). Even though the selected concentrations are in accordance
with the ones used in cell biology experiments of similar design (Gotlieb et al., 2008; Rattan et al., 2011a;
Shank et al., 2012; Wu et al., 2012; Lengyel et al., 2015; Patel et al., 2015; Dos Santos Guimarães et al.,
2018; Yang et al., 2019), it is important to note that they are supra-physiological. Type 2 diabetic patients
treated with metformin have less than 50 μM concentration of this drug in their blood (Martin-Castillo
et al., 2010). However, it has been shown that tissues can accumulate metformin and thus higher
concentrations can be reached locally (Owen et al., 2000). In fact, one already presented study by Wu et
al. (2012), that found SKOV3 proliferation to be effectively inhibited with ~20 mM without apoptosis,
postulates that this suggests that such doses are potentially not directly toxic and are at a therapeutic
level. Refined translation of this into clinical use would need to be developed, which is a fine opportunity
for future research. Regarding other future research possibilities, since the irradiation part of one of the
experiments was performed only once, it would be wise to replicate that particular experiment. Future
experiments could also include higher metformin concentrations than 20 mM, if desired, but it is essential
to apply metformin to cells kept in long-term culture. It could also be beneficial to perform more
apoptosis experiments with the adjusted setup, since the current experiment lacked the data on this
cellular process. Apoptosis is often investigated in cancer-related experiments, because acquired
resistance to chemotherapeutic therapies and the consequent cancer progression can be caused by faults
in the apoptotic machinery (Patel et al., 2015). Most importantly, it is necessary to investigate whether
high metformin concentrations affect specifically the HR-mediated DNA repair pathway. If the findings
are positive, it would also be a good idea to perform the same experiments with more HR-proficient and
HR-deficient commercial cell lines (provided they do not need insulin in the medium). In the case of
encouraging findings, it would also be worthy to perform the experiments with primary ovarian cancer
cells instead of commercial cell lines, because primary cells better resemble the physiological state of
cancer cells in vivo, and thus, more meaningful data can be obtained using them (Patel et al., 2015).
In conclusion, this thesis work provides preliminary evidence that metformin concentrations of at least
20 mM in combination with IR are effective in increasing DNA damage and reducing proliferation even
in an HR-proficient HGSOC cell line, and thereby lays the groundwork for more detailed investigations
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of metformin’s suppressive effects on HR-proficient high-grade serous ovarian tumors. In the long term,
such studies can provide novel, well-tolerated chemo-sensitization options for patients with hard-to-treat
HGSOC.
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APPENDICES
Appendix A: Table of Resources
Name, Manufacturer/Source, Additional Information
Cells
 Kuramochi Commercial Cell Line. Initial Passage 20. Source: Genome
Stability Group (Kauppi Lab), Biomedicum 1, University of Helsinki.
 OVCAR4 Commercial Cell Line. Initial Passage x+3 (explanation: “x”
means unknown – laboratory received the cells not knowing the exact
passage, and then the cells were additionally passaged 3 times afterward).
Source: Genome Stability Group (Kauppi Lab), Biomedicum 1,
University of Helsinki.
Chemicals,
Nutrients etc.
 Calcium Chloride, fused, granular, general purpose grade. Fisher
Scientific, C/1400/53.
 Magnesium Chloride hexa-hydrate, BioXtra, ≥ 99,0 %. Sigma-Aldrich,
M2670-100G.
 Phosphate-Buffered Saline (PBS) Tablets. Medicago, 09-9400-100.
 Bovine Serum Albumin (BSA), fatty acids free lyophilized; stored in 4
⁰C. biowest, P6156- 100GR.
 Glycine, ≥ 99 %. Sigma-Aldrich, G8898-500G.
 Triton® X-100. Fisher Scientific, BP151-100.
 RPMI 1640 Growth Medium. Corning®, 15-040-CVR.
 Fetal Bovine Serum (FBS). gibco, Thermo Fisher Scientific, 10270-106.
It is heated to 56 ⁰C to inactivate the complement, then aliquots are made
and stored in -20 ⁰C.
 Glutamine. GlutaMAXTM-I(100X), gibco® by Life Technologies, 35050-
038.
 Penicillin-streptomycin (P/S) ([+] 10,000 units/ml penicillin and [+]
10,000 µg/ml streptomycin). gibco® by Life Technologies, 15140-122.
 0,25 % Trypsin/EDTA (1X). Life Technologies Limited, 25200-056.
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 Dimethyl Sulfoxide (DMSO). MP Biomedicals, 196055.
 Trypan Blue Stain, 0,4 %. Logos Biosystems, T13001.
 Metformin Hydrochloride. MP Biomedicals, 151691. Molecular Weight:
165,63 g/mol.
 Paraformaldehyde (PFA), 96 %, extra pure. Acros Organics, 416780010.
 Hoechst 33342, trihydrochloride, trihydrate, 10 mg/ml; stored in 4 ⁰C.
invitrogen, Molecular Probes by Life Technologies, H3570.
Antibodies
 Mouse anti-γH2AX (Ser139+140), Primary Antibody; stored in -20 ⁰C.
abcam, 22551.
 Rabbit anti-Ki67, Primary Antibody; stored in -20 ⁰C. abcam, 15580.
 Rabbit anti-cCasp3, Primary Antibody; stored in -20 ⁰C. Cell Signaling
Technology, 9664.
 Goat anti-Mouse IgG Alexa Fluor 488, Secondary Antibody; stored in 4
⁰C. Molecular Probes, A 11029.
 Goat anti-Mouse IgG Alexa Fluor 647, Secondary Antibody; stored in 4
⁰C. Molecular Probes, A 21245.
Microscopy
Equipment
 InvitrogenTM EVOSTM XL Core Cell Imaging System. Thermo Fisher
Scientific.
 Thermo Cellinsight High Content Imager. Thermo Fisher Scientific.
 ImageXpress® Pico Automated Cell Imaging System. Molecular
Devices.
Other Devices and
Equipment
 HERAfreezeTM HLE Series Freezer (-80 ⁰C). Thermo Scientific. Model
Number: HLE50086V; Item Number: 155VE5CO2M; Serial Number:
1119782801190221.
 Ultra Low Freezer (-150 ⁰C). Sanyo, MDF-C2156VAN.
 CoolCell® LX Cell Freezing Containers. BioCision.
 BIOWIZARD Platinum 130 SF Class II Laminar Flow Cabinet. Kojair.
 Heraeus BB 15 Function Line Incubator. Thermo Fisher Scientific.
 Isotemp® GPD 10 Water Bath. Fisher Scientific.
 Eppendorf® Centrifuge 5804R.
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 Luna-flTM Dual Fluorescence Cell Counter. Logos Biosystems.
 LunaTM Cell Counting Slides. Logos Biosystems, L12001.
 Mini See-Saw Rocker SSM4. Stuart.
 BIOHIT Sartorius mLINE® mechanical pipette, 8-channel (30-300 µl).
 BIOHIT Proline Plus single channel pipette (0,5-10 µl).
 BIOHIT m (10-100 µl) pipette.
 BIOHIT Proline Plus single channel (100-1000 µl) pipette.
 BIOHIT MidiPlus pipette.
 BioLite Tissue Culture Dish, 100 mm. Thermo Fisher Scientific, 130182.
 NunclonTM Delta Surface 96-Well Cell Culture Plates. Thermo Fisher
Scientific, 167008.
 Nalgene® Cryoware Cryogenic Vials. Thermo Fisher Scientific, 5000-
0020.
 Corning® 50 ml Centrifuge Tube, CentriStarTM Cap. 430829.
 Corning® 15 ml Centrifuge Tube, CentriStarTM Cap. 430791.
 Eppendorf Tubes®, 5,0 ml. 0030119487.
 EmeraldTM Syringe, 10 ml. Becton Dickinson, 307736.
 Inject® Luer Solo Syringe, 20 ml. B. Braun, 4606205V.
 MicrolanceTM 3, 20G 1 ½“ - Nr. 1, 0,9 x 40 mm. Becton Dickinson,
301300.
 Millex®GP Filter Unit 0,22 µm, Millipore Express® PES Membrane.
Merck Millipore, SLGP033RS.
 Parafilm® M Laboratory Film. Bemis, PM-999.
Software
 Cellomics Navigator – software for working with Thermo Cellinsight.
 MD.CellReporterXpress® by Molecular Devices® – software for working
with ImageXpress® Pico.
 ImageJ – public domain Java image processing program.
Fiji – image processing package with a variety of plugins for scientific
image analysis.
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URL: https://imagej.net/Fiji
 Online file conversion tool (CSV to XLSX).
URL: https://convertio.co/csv-xlsx/
 Online calculator for statistical significance.
URL: https://www.medcalc.org/calc/fisher.php
 MS Paint – basic graphics and painting program for creating custom
images
 Adobe Photoshop CS6 – graphics editing software for creating custom
images
Solutions Made in
the Laboratory
 Growth Medium: RPMI 1640 growth medium is supplemented with 10
% FBS, 2 mM glutamine, and 1 % P/S.
 PBS: 1 PBS tablet is dissolved in 1 l of MilliQ.
 PBS++: 1 l of PBS is supplemented with 1 mM CaCl2 and 0,5 mM MgCl2.
 2 % PFA/PBS++: PFA is diluted in PBS++ to make a 2 % solution, which
is then stored in -20 ⁰C.
 Permeabilization buffer: 100 ml of PBS++ is supplemented with 0,2 %
Triton X-100.
 Staining buffer: 250 ml of PBS is supplemented with 0,5 % BSA, 0,15 %
glycine, and 0,1 % Triton X-100; stored in 4 ⁰C.
Appendix B: Macros Used in the First Experiment
Macro for Channel 1 – Hoechst:
run("Auto Threshold", "method=Li white");
run("Watershed");
run("Watershed");
run("Analyze Particles...", "size=200-Infinity pixel show=[Masks] exclude summarize");
run("Create Selection");
run("Make Inverse");
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run("Copy");
Macro for Channel 2 – γH2AX:
run("Paste");
setBackgroundColor(0, 0, 0);
run("Clear", "slice");
run("Select None");
run("Duplicate...", "title=gH2Ax.TIF");
run("Auto Threshold", "method=Default ignore_black ignore_white white");
run("Despeckle");
run("Analyze Particles...", "size=150-Infinity pixel show=Masks exclude summarize");
Macro for Channel 3 – Ki67:
run("Paste");
run("Undo");
run("Clear", "slice");
run("Select None");
run("Duplicate...", "title=Ki67.TIF");
run("Auto Threshold", "method=Default ignore_black ignore_white white");
run("Despeckle");
run("Options...", "iterations=3 count=2 black pad do=Dilate");
run("Analyze Particles...", "size=150-Infinity pixel show=Masks exclude summarize");
Macro for Channel 3 – cCasp3:
run("Subtract Background...", "rolling=200");
run("Paste");
run("Undo");
run("Clear Outside");
run("Select None");
run("Duplicate...", "title=cCasp3.TIF");
run("Out [-]");
run("Enhance Contrast...", "saturated=0.3");
run("Auto Threshold", "method=RenyiEntropy white");
run("Options...", "iterations=21 count=3 black do=Dilate");
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run("Analyze Particles...", "size=400-Infinity pixel show=[Bare Outlines] exclude summarize");
run("Out [-]");
Appendix C: γH2AX Results from Different Staining Combinations
Figure 1. γH2AX results from the γH2AX+Ki67 staining combination used for Kuramochi cells in the first
experiment.
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Figure 2. γH2AX results from the γH2AX+cCasp3 staining combination used for Kuramochi cells in the first
experiment.
Figure 3. γH2AX results from the γH2AX+Ki67 staining combination used for Kuramochi cells in the second
experiment.
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Figure 4. γH2AX results from the γH2AX+cCasp3 staining combination used for Kuramochi cells in the second
experiment.
Figure 5. γH2AX results from the γH2AX+Ki67 staining combination used for OVCAR4 cells in the second
experiment.
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Figure 6. γH2AX results from the γH2AX+cCasp3 staining combination used for OVCAR4 cells in the second
experiment.
Figure 7. γH2AX results from the γH2AX+Ki67 staining combination used for Kuramochi cells in the no IR+4h
part of the third experiment.
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Figure 8. γH2AX results from the γH2AX+cCasp3 staining combination used for Kuramochi cells in the no IR+4h
part of the third experiment.
Figure 9. γH2AX results from the γH2AX+Ki67 staining combination used for OVCAR4 cells in the no IR+4h
part of the third experiment.
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Figure 10. γH2AX results from the γH2AX+cCasp3 staining combination used for OVCAR4 cells in the no IR+4h
part of the third experiment.
Figure 11. γH2AX results from the γH2AX+Ki67 staining combination used for Kuramochi cells in the no IR+24h
part of the third experiment.
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Figure 12. γH2AX results from the γH2AX+cCasp3 staining combination used for Kuramochi cells in the no
IR+24h part of the third experiment.
Figure 13. γH2AX results from the γH2AX+Ki67 staining combination used for OVCAR4 cells in the no IR+24h
part of the third experiment.
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Figure 14. γH2AX results from the γH2AX+cCasp3 staining combination used for OVCAR4 cells in the no
IR+24h part of the third experiment.
Figure 15. γH2AX results from the γH2AX+Ki67 staining combination used for Kuramochi cells in the IR+4h
part of the third experiment.
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Figure 16. γH2AX results from the γH2AX+cCasp3 staining combination used for Kuramochi cells in the IR+4h
part of the third experiment.
Figure 17. γH2AX results from the γH2AX+Ki67 staining combination used for OVCAR4 cells in the IR+4h part
of the third experiment.
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Figure 18. γH2AX results from the γH2AX+cCasp3 staining combination used for OVCAR4 cells in the IR+4h
part of the third experiment.
Figure 19. γH2AX results from the γH2AX+Ki67 staining combination used for Kuramochi cells in the IR+24h
part of the third experiment.
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Figure 20. γH2AX results from the γH2AX+cCasp3 staining combination used for Kuramochi cells in the IR+24h
part of the third experiment.
Figure 21. γH2AX results from the γH2AX+Ki67 staining combination used for OVCAR4 cells in the IR+24h
part of the third experiment.
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Figure 22. γH2AX results from the γH2AX+cCasp3 staining combination used for OVCAR4 cells in the IR+24h
part of the third experiment.
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Appendix D: Full Pooled no IR γH2AX and Ki67 Data from All Three Experiments.
Figure 23. Pooled γH2AX results from all non-irradiated Kuramochi cells.
Figure 24. Pooled γH2AX results from all non-irradiated OVCAR4 cells.
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Figure 25. Pooled Ki67 results from all non-irradiated Kuramochi cells.
Figure 26. Pooled Ki67 results from all non-irradiated OVCAR4 cells.
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Appendix E: Numbers of Analyzed Nuclei with Numbers of γH2AX-, Ki67-, and cCasp3-Positives
in Each Condition Throughout All Three Experiments. Abbreviations: pl. – plate, met. – metformin,
K – Kuramochi, O – OVCAR4, (m) – manual scoring, n/a – not available.
Condition
γH2AX-Ki67
staining:
γH2AX-positive
nuclei / all
nuclei
γH2AX-cCasp3
staining:
γH2AX-positive
nuclei / all
nuclei
Combined
γH2AX
stainings: total
number of
γH2AX-positive
nuclei / total
number of
nuclei
Ki67-positive
nuclei / all
nuclei
cCasp3-positive
nuclei / all
nuclei
The 1st experiment
24h pl.,
0 mM met.
K: 157 / 377
O: n/a
K: 69 / 218
O: n/a
K: 226 / 595
O: n/a
K: 252 / 377
O: n/a
K: 80 / 218
O: n/a
24h pl.,
0,5 mM met.
K: 57 / 130
O: n/a
K: 45 / 149
O: n/a
K: 102 / 279
O: n/a
K: 90 / 130
O: n/a
K: 60 / 149
O: n/a
24h pl.,
5 mM met.
K: 60 / 143
O: n/a
K: 93 / 273
O: n/a
K: 153 / 416
O: n/a
K: 83 / 143
O: n/a
K: 112 / 273
O: n/a
24h pl.,
25 mM met.
K: 36 / 67
O: n/a
K: 87 / 190
O: n/a
K: 123 / 257
O: n/a
K: 21 / 67
O: n/a
K: 112 / 190
O: n/a
48h pl.,
0 mM met.
K: 162 / 316
O: n/a
K: 286 / 669
O: n/a
K: 448 / 985
O: n/a
K: 223 / 316
O: n/a
K: 124 / 669
O: n/a
48h pl.,
0,5 mM met.
K: 172 / 405
O: n/a
K: 164 / 478
O: n/a
K: 336 / 883
O: n/a
K: 291 / 405
O: n/a
K: 121 / 478
O: n/a
48h pl.,
5 mM met.
K: 167 / 352
O: n/a
K: 131 / 462
O: n/a
K: 298 / 814
O: n/a
K: 243 / 352
O: n/a
K: 142 / 462
O: n/a
48h pl.,
25 mM met.
K: 31 / 57
O: n/a
K: 21 / 37
O: n/a
K: 52 / 94
O: n/a
K: 21 / 57
O: n/a
K: 35 / 37
O: n/a
72h pl.,
0 mM met.
K: 206 / 576
O: n/a
K: 437 / 1297
O: n/a
K: 643 / 1873
O: n/a
K: 338 / 576
O: n/a
K: 100 / 1297
O: n/a
72h pl.,
0,5 mM met.
K: 307 / 796
O: n/a
K: 192 / 600
O: n/a
K: 499 / 1396
O: n/a
K: 461 / 796
O: n/a
K: 139 / 600
O: n/a
72h pl.,
5 mM met.
K: 155 / 476
O: n/a
K: 192 / 654
O: n/a
K: 347 / 1130
O: n/a
K: 285 / 476
O: n/a
K: 147 / 654
O: n/a
72h pl., K: 20 / 33 K: 46 / 92 K: 66 / 125 K: 13 / 33 K: 72 / 92
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25 mM met. O: n/a O: n/a O: n/a O: n/a O: n/a
The 2nd experiment
24h pl.,
0 mM met.
K: 486 / 935
O: 433 / 710
K: 661 / 1316
O: 618 / 982
K: 1147 / 2251
O: 1051 / 1692
K: 785 / 935
O: 346 / 710
K: n/a
O: n/a
24h pl.,
5 mM met.
K: 1361 / 2422
O: 930 / 1573
K: 1626 / 2719
O: 620 / 1022
K: 2987 / 5141
O: 1550 / 2595
K: 1853 / 2422
O: 724 / 1573
K: n/a
O: n/a
24h pl.,
10 mM met.
K: 1642 / 2700
O: 157 / 208
K: 1649 / 3011
O: 371 / 630
K: 3291 / 5711
O: 528 / 838
K: 2115 / 2700
O: 99 / 208
K: n/a
O: n/a
24h pl.,
15 mM met.
K: 1556 / 2212
O: 678 / 937
K: 1619 / 2415
O: 279 / 363
K: 3175 / 4627
O: 957 / 1300
K: 1682 / 2212
O: 441 / 937
K: n/a
O: n/a
24h pl.,
20 mM met.
K: 2569 / 3734
O: 863 / 1290
K: 2462 / 3743
O: 668 / 831
K: 5031 / 7477
O: 1531 / 2121
K: 2888 / 3734
O: 583 / 1290
K: n/a
O: n/a
48h pl.,
0 mM met.
K: 4122 / 10732
O: 1972 / 5359
K: 5120 / 13966
O: 1704 / 4200
K: 9242 / 24698
O: 3676 / 9559
K: 9170 / 10732
O: 2661 / 5359
K: n/a
O: n/a
48h pl.,
5 mM met.
K: 2395 / 4653
O: 3555 / 10325
K: 5144 / 12964
O: 1756 / 4801
K: 7539 / 17617
O: 5311 / 15126
K: 3921 / 4653
O: 4816 / 10325
K: n/a
O: n/a
48h pl.,
10 mM met.
K: 3358 / 5621
O: 1500 / 4452
K: 5482 / 12047
O: 3061 / 8065
K: 8940 / 17668
O: 4561 / 12517
K: 4407 / 5621
O: 2149 / 4452
K: n/a
O: n/a
48h pl.,
15 mM met.
K: 4224 / 6329
O: 3247 / 8255
K: 5631 / 9592
O: 3199 / 7149
K: 9855 / 15921
O: 6446 / 15404
K: 4675 / 6329
O: 4301 / 8255
K: n/a
O: n/a
48h pl.,
20 mM met.
K: 4354 / 6064
O: 3156 / 6247
K: 6057 / 9154
O: 3411 / 5820
K: 10414 / 15218
O: 6567 / 12067
K: 4192 / 6064
O: 2717 / 6247
K: n/a
O: n/a
The 3rd experiment
24h+no IR+4h
pl., 0 mM met.
K: 108 / 233 (m)
O: 88 / 219 (m)
K: 141 / 310 (m)
O: 81 / 208 (m)
K: 249 / 543 (m)
O: 169 / 427 (m)
K: 2216 / 2872
O: 1045 / 1746
K: n/a
O: n/a
24h+no IR+4h
pl., 0,5 mM met.
K: 109 / 225 (m)
O: 91 / 219 (m)
K: 110 / 240 (m)
O: 87 / 229 (m)
K: 219 / 465 (m)
O: 178 / 448 (m)
K: 3641 / 4231
O: 1237 / 2919
K: n/a
O: n/a
24h+no IR+4h
pl., 5 mM met.
K: 117 / 215 (m)
O: 85 / 215 (m)
K: 110 / 227 (m)
O: 79 / 200 (m)
K: 227 / 442 (m)
O: 164 / 415 (m)
K: 2246 / 2660
O: 755 / 1337
K: n/a
O: n/a
24h+no IR+4h
pl., 10 mM met.
K: 126 / 253 (m)
O: 102 / 229 (m)
K: 112 / 220 (m)
O: 97 / 234 (m)
K: 238 / 473 (m)
O: 199 / 463 (m)
K: 3370 / 4010
O: 1677 / 2857
K: n/a
O: n/a
24h+no IR+4h
pl., 20 mM met.
K: 125 / 205 (m)
O: 112 / 250 (m)
K: 124 / 199 (m)
O: 105 / 249 (m)
K: 249 / 404 (m)
O: 217 / 499 (m)
K: 3297 / 4079
O: 1604 / 2703
K: n/a
O: n/a
48h+no IR+4h
pl., 0 mM met.
K: 86 / 209 (m)
O: 112 / 240 (m)
K: 128 / 298 (m)
O: 121 / 260 (m)
K: 214 / 507 (m)
O: 233 / 500 (m)
K: 8454 / 11231
O: 1704 / 2752
K: n/a
O: n/a
48h+no IR+4h
pl., 0,5 mM met.
K: 150 / 315 (m)
O: 94 / 204 (m)
K: 116 / 232 (m)
O: 99 / 208 (m)
K: 266 / 547 (m)
O: 193 / 412 (m)
K: 10526 / 12711
O: 5870 / 9097
K: n/a
O: n/a
103
48h+no IR+4h
pl., 5 mM met.
K: 136 / 268 (m)
O: 114 / 238 (m)
K: 109 / 208 (m)
O: 89 / 204 (m)
K: 245 / 476 (m)
O: 203 / 442 (m)
K: 10446 / 13010
O: 4677 / 8065
K: n/a
O: n/a
48h+no IR+4h
pl., 10 mM met.
K: 167 / 287 (m)
O: 112 / 240 (m)
K: 181 / 323 (m)
O: 93 / 213 (m)
K: 348 / 610 (m)
O: 205 / 453 (m)
K: 6560 / 7819
O: 923 / 1639
K: n/a
O: n/a
48h+no IR+4h
pl., 20 mM met.
K: 165 / 270 (m)
O: 155 / 331 (m)
K: 125 / 224 (m)
O: 92 / 200 (m)
K: 290 / 494 (m)
O: 247 / 531 (m)
K: 5048 / 7486
O: 1476 / 3472
K: n/a
O: n/a
24h+no IR+24h
pl., 0 mM met.
K: 109 / 231 (m)
O: 94 / 212 (m)
K: 96 / 241 (m)
O: 115 / 263 (m)
K: 205 / 472 (m)
O: 209 / 475 (m)
K: 3189 / 3838
O: 5655 / 10770
K: n/a
O: n/a
24h+no IR+24h
pl., 0,5 mM met.
K: 92 / 195 (m)
O: 114 / 265 (m)
K: 118 / 248 (m)
O: 99 / 226 (m)
K: 210 / 443 (m)
O: 213 / 491 (m)
K: 5550 / 6515
O: 4972 / 8864
K: n/a
O: n/a
24h+no IR+24h
pl., 5 mM met.
K: 116 / 238 (m)
O: 105 / 234 (m)
K: 116 / 238 (m)
O: 109 / 241 (m)
K: 232 / 476 (m)
O: 214 / 475 (m)
K: 4048 / 4734
O: 5595 / 10480
K: n/a
O: n/a
24h+no IR+24h
pl., 10 mM met.
K: 113 / 222 (m)
O: 161 / 376 (m)
K: 109 / 218 (m)
O: 128 / 286 (m)
K: 222 / 440 (m)
O: 289 / 662 (m)
K: 2872 / 3439
O: 4602 / 9385
K: n/a
O: n/a
24h+no IR+24h
pl., 20 mM met.
K: 127 / 231 (m)
O: 256 / 598 (m)
K: 106 / 206 (m)
O: 105 / 228 (m)
K: 233 / 437 (m)
O: 361 / 826 (m)
K: 1573 / 2125
O: 2165 / 4829
K: n/a
O: n/a
48h+no IR+24h
pl., 0 mM met.
K: 80 / 210 (m)
O: 114 / 281 (m)
K: 109 / 288 (m)
O: 128 / 321 (m)
K: 189 / 498 (m)
O: 242 / 602 (m)
K: 13590 / 21163
O: 160 / 274 (m)
K: n/a
O: n/a
48h+no IR+24h
pl., 0,5 mM met.
K: 118 / 261 (m)
O: 97 / 223 (m)
K: 90 / 217 (m)
O: 134 / 310 (m)
K: 208 / 478 (m)
O: 231 / 533 (m)
K: 15529 / 22754
O: 8888 / 17227
K: n/a
O: n/a
48h+no IR+24h
pl., 5 mM met.
K: 118 / 258 (m)
O: 112 / 255 (m)
K: 90 / 205 (m)
O: 148 / 357 (m)
K: 208 / 463 (m)
O: 260 / 612 (m)
K: 15069 / 21060
O: 142 / 246 (m)
K: n/a
O: n/a
48h+no IR+24h
pl., 10 mM met.
K: 101 / 200 (m)
O: 120 / 263 (m)
K: 124 / 272 (m)
O: 95 / 209 (m)
K: 225 / 472 (m)
O: 215 / 472 (m)
K: 12979 / 18013
O: 117 / 209 (m)
K: n/a
O: n/a
48h+no IR+24h
pl., 20 mM met.
K: 124 / 213 (m)
O: 150 / 312 (m)
K: 133 / 233 (m)
O: 100 / 217 (m)
K: 257 / 446 (m)
O: 250 / 529 (m)
K: 5795 / 9480
O: 2870 / 6624
K: n/a
O: n/a
24h+IR+4h pl.,
0 mM met.
K: 269 / 279 (m)
O: 345 / 345 (m)
K: 395 / 395 (m)
O: 227 / 227 (m)
K: 664 / 674 (m)
O: 572 / 572 (m)
K: 4461 / 5547
O: 2477 / 5329
K: n/a
O: n/a
24h+IR+4h pl.,
0,5 mM met.
K: 214 / 218 (m)
O: 216 / 217 (m)
K: 244 / 248 (m)
O: 247 / 250 (m)
K: 458 / 466 (m)
O: 463 / 467 (m)
K: 3866 / 4625
O: 1450 / 4508
K: n/a
O: n/a
24h+IR+4h pl.,
5 mM met.
K: 255 / 261 (m)
O: 242 / 242 (m)
K: 277 / 280 (m)
O: 238 / 241 (m)
K: 532 / 541 (m)
O: 480 / 483 (m)
K: 1997 / 2487
O: 1140 / 2825
K: n/a
O: n/a
24h+IR+4h pl.,
10 mM met.
K: 232 / 238 (m)
O: 244 / 244 (m)
K: 237 / 241 (m)
O: 218 / 219 (m)
K: 469 / 479 (m)
O: 462 / 463 (m)
K: 1702 / 2323
O: 2110 / 4537
K: n/a
O: n/a
24h+IR+4h pl.,
20 mM met.
K: 213 / 214 (m)
O: 210 / 211 (m)
K: 263 / 264 (m)
O: 212 / 212 (m)
K: 476 / 478 (m)
O: 422 / 423 (m)
K: 2764 / 4140
O: 2490 / 5334
K: n/a
O: n/a
48h+IR+4h pl., K: 212 / 215 (m) K: 256 / 262 (m) K: 468 / 477 (m) K: 4197 / 5296 K: n/a
104
0 mM met. O: 239 / 242 (m) O: 238 / 240 (m) O: 477 / 482 (m) O: 171 / 271 (m) O: n/a
48h+IR+4h pl.,
0,5 mM met.
K: 329 / 333 (m)
O: 295 / 297 (m)
K: 228 / 231 (m)
O: 239 / 242 (m)
K: 557 / 564 (m)
O: 534 / 539 (m)
K: 9810 / 11852
O: 7615 / 12917
K: n/a
O: n/a
48h+IR+4h pl.,
5 mM met.
K: 301 / 302 (m)
O: 272 / 274 (m)
K: 225 / 227 (m)
O: 250 / 252 (m)
K: 526 / 529 (m)
O: 522 / 526 (m)
K: 9049 / 10918
O: 3780 / 7013
K: n/a
O: n/a
48h+IR+4h pl.,
10 mM met.
K: 262 / 263 (m)
O: 262 / 264 (m)
K: 224 / 228 (m)
O: 280 / 284 (m)
K: 486 / 491 (m)
O: 542 / 548 (m)
K: 4579 / 5446
O: 5948 / 12343
K: n/a
O: n/a
48h+IR+4h pl.,
20 mM met.
K: 206 / 208 (m)
O: 280 / 282 (m)
K: 307 / 307 (m)
O: 252 / 253 (m)
K: 513 / 515 (m)
O: 532 / 535 (m)
K: 3936 / 5551
O: 4825 / 11318
K: n/a
O: n/a
24h+IR+24h
pl., 0 mM met.
K: 190 / 209 (m)
O: 162 / 241 (m)
K: 188 / 215 (m)
O: 140 / 212 (m)
K: 378 / 424 (m)
O: 302 / 453 (m)
K: 1692 / 2041
O: 7818 / 12116
K: n/a
O: n/a
24h+IR+24h
pl., 0,5 mM met.
K: 222 / 248 (m)
O: 151 / 249 (m)
K: 248 / 290 (m)
O: 129 / 209 (m)
K: 470 / 538 (m)
O: 280 / 458 (m)
K: 2646 / 2991
O: 5985 / 8290
K: n/a
O: n/a
24h+IR+24h
pl., 5 mM met.
K: 228 / 260 (m)
O: 173 / 279 (m)
K: 195 / 213 (m)
O: 133 / 208 (m)
K: 423 / 473 (m)
O: 306 / 487 (m)
K: 2727 / 3236
O: 5446 / 7632
K: n/a
O: n/a
24h+IR+24h
pl., 10 mM met.
K: 199 / 213 (m)
O: 171 / 244 (m)
K: 202 / 216 (m)
O: 146 / 207 (m)
K: 401 / 429 (m)
O: 317 / 451 (m)
K: 2722 / 3248
O: 2960 / 3956
K: n/a
O: n/a
24h+IR+24h
pl., 20 mM met.
K: 216 / 225 (m)
O: 209 / 251 (m)
K: 211 / 220 (m)
O: 206 / 260 (m)
K: 427 / 445 (m)
O: 415 / 511 (m)
K: 3132 / 4543
O: 1300 / 2239
K: n/a
O: n/a
48h+IR+24h
pl., 0 mM met.
K: 219 / 246 (m)
O: 177 / 228 (m)
K: 213 / 243 (m)
O: 163 / 223 (m)
K: 432 / 489 (m)
O: 340 / 451 (m)
K: 8859 / 15169
O: 182 / 233 (m)
K: n/a
O: n/a
48h+IR+24h
pl., 0,5 mM met.
K: 200 / 222 (m)
O: 162 / 250 (m)
K: 198 / 222 (m)
O: 131 / 207 (m)
K: 398 / 444 (m)
O: 293 / 457 (m)
K: 11085 / 16818
O: 168 / 206 (m)
K: n/a
O: n/a
48h+IR+24h
pl., 5 mM met.
K: 204 / 216 (m)
O: 142 / 201 (m)
K: 191 / 216 (m)
O: 130 / 205 (m)
K: 395 / 432 (m)
O: 272 / 406 (m)
K: 10878 / 15272
O: 184 / 237 (m)
K: n/a
O: n/a
48h+IR+24h
pl., 10 mM met.
K: 208 / 222 (m)
O: 170 / 227 (m)
K: 198 / 213 (m)
O: 174 / 244 (m)
K: 406 / 435 (m)
O: 344 / 471 (m)
K: 8642 / 12879
O: 188 / 229 (m)
K: n/a
O: n/a
48h+IR+24h
pl., 20 mM met.
K: 228 / 233 (m)
O: 205 / 226 (m)
K: 217 / 227 (m)
O: 226 / 231 (m)
K: 445 / 460 (m)
O: 431 / 457 (m)
K: 4832 / 8096
O: 1844 / 4748
K: n/a
O: n/a
